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ABSTRACT OF THE DISSERTATION 
 
CRTC2 Regulates Plasma Cell Metabolism and Survival  
to Maintain Humoral Immune Responses  
by 
Jason S. Hong 
Doctor of Philosophy in Cellular and Molecular Pathology 
University of California, Los Angeles, 2020 
Professor Michael A. Teitell, Chair 
 
The humoral immune response is mediated by antigen activated B cells that 
have terminally differentiated into antibody secreting cells (ASCs). The ASC pool is 
composed of short-lived plasma cells (SLPCs) and long-lived plasma cells (LLPCs) that 
secrete antigen-specific antibodies to clear an infection and maintain long-term 
protective antibody titers to prevent subsequent reinfections. SLPCs have generally 
been viewed to be formed from T cell-independent immune responses and localized in 
the spleen. LLPCs have been viewed to be formed from T cell-dependent immune 
responses and localized in the bone marrow. However, regardless of the type of 
stimulating antigen, ASCs of varying lifespans, both SLPCs and LLPCs are found in the 
spleen and bone marrow. Currently, it remains unclear as to what factors and pathways 
regulate PC longevity.  
Our laboratory previously identified the CREB coactivator CRTC2 as a regulator 
of ASC differentiation. DNA double strand breaks associated with class switch 
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recombination activates a signaling pathway in human germinal center (GC) B cells that 
results in the phosphorylation and inactivation of CRTC2. Phosphorylated CRTC2 is re-
localized to the cytoplasm and CRTC2 target genes are down-regulated. Dysregulation 
of CRTC2 activity through over-expression of a nucleus-localized and constitutively 
active form of CRTC2 (CRTC2-AA) in human tonsillar B cells, prevented GC B cells 
from exiting the GC reaction and inhibited ASC differentiation. However, it remained 
unclear whether the function of CRTC2 in this in vitro differentiation system would be 
recapitulated in vivo and whether CRTC2 played any other roles in an in vivo humoral 
immune response.  
 To evaluate these questions, we generated a transgenic (TG) mouse model 
which expresses CRTC2-AA at all stages of B cell development. Using these TG mice, 
we demonstrate that Crtc2 repression in PCs is an intrinsic requirement for PC 
metabolic fitness. Sustained CRTC2 activity shortened the survival of splenic and bone 
marrow PCs which resulted in the reduction of long-lived PCs and antibody deficits in 
response to immunizations and acute viral infection. We further demonstrated that TG 
PCs adopt characteristics associated with SLPCs which include reduced antibody 
secretion, glycolysis, oxidative metabolism, and spare respiratory capacity. 
Mechanistically, Crtc2 repression is necessary for the fidelity of PC gene expression 
and mRNA alternative-splicing programs, with both programs altered in TG PCs. 
Combined, our results show that Crtc2 repression in PCs must occur to support PC 
metabolism and extend PC survival and lifespan during a humoral immune response. 
We hypothesize that the level of Crtc2 repression in differentiated ASCs determines 
metabolic fitness and ultimately PC survival and longevity in the bone marrow. 
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CHAPTER 1: 
 
 
Introduction 
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The humoral immune response represents one arm of the adaptive immune 
system. B cells that are antigen activated, rapidly proliferate and differentiate into 
transient plasmablasts (PBs) or plasma cells (PCs). These antibody secreting cells 
(ASCs) represent a small, but critical effector population of the B cell lineage 
responsible for neutralizing pathogens and maintaining long-term humoral immunity1, 2. 
Since the discovery of antibody mediated immunity well over 100 years ago, much has 
been learned about this critically important cell population3. 
 
B CELL DEVLOPMENT 
In humans and mice, B cells are continuously generated from hematopoietic 
stem cells in the bone marrow. Developing B cells pass through several developmental 
checkpoints that ensure immunoglobulin genes are completely assembled from a 
diverse pool of gene segments in a process known as V(D)J recombination. This 
process results in the expression of a diverse repertoire of membrane bound antigen 
receptors, or B cell receptors (BCRs), which allow for the recognition of a near limitless 
number of unique antigens4. Both the BCR and the secreted form of the BCR, known as 
an antibody, are unique to each B cell and binds antigens with varying levels of affinity. 
A single BCR or antibody molecule is composed of four polypeptide chains (2 heavy 
and 2 light) that are held together by disulfide bonds to form a Y-shaped molecule. The 
N-terminus regions, or the tips of the Y, represent the variable regions which recognize 
and bind antigen. The C-terminus, or the base of the Y, forms the constant region which 
determines the isotype of the molecule. Antibodies of different isotypes (IgM, IgD, IgG, 
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IgE, and IgA) differ in their effector functions and localizations to ensure proper immune 
response to a given pathogen or infection5. 
The developmental stages in the bone marrow progress sequentially from pro-B, 
pre-B, to immature B cells. Immature B cells that retain low-level BCR signaling are 
positively selected and retained, whereas those incapable of signaling through the BCR 
are eliminated. Many B cell clones with strong reactivity to self-antigens are eliminated 
through negative selection. Importantly, much of the BCR diversity that was generated 
earlier in the bone marrow is eliminated at this stage in development6. Immature B cells 
will leave the bone marrow and home to the spleen where they differentiate into 
transitional B cells and mature further into follicular (FO) or marginal-zone (MZ) B cells. 
These mature B cells are retained in the spleen while FO B cells recirculate through the 
bone marrow and other secondary lymphoid organs (SLOs)5, 7.  
 
B CELL ACTIVATION AND TERMINAL DIFFERENTIATION 
Mature B cells remain quiescent until they are activated via BCR engagement to 
their cognate antigens. B cell activation results in cell proliferation and differentiation 
and can be elicited by either a T cell-independent (TI) or T cell-dependent (TD) antigen. 
B cells activated by TI antigens, which include large carbohydrates or phospholipids 
with repeating epitopes, do not require T cell help as these antigens are capable of 
cross-linking multiple BCRs and/or activating toll-like receptors (TLRs). A TI immune 
response rapidly generates PBs that secrete non-mutated low-affinity antibodies8. B 
cells activated by a protein or TD antigen, rapidly proliferate and differentiate into PBs in 
an extrafollicular response which produce the first wave of unmutated low affinity 
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antibodies. Concurrent with the extrafollicular response, activated B cells that have 
acquired T cell help, can form histological structures called germinal centers (GCs). 
Within GCs, rapidly proliferating B cells undergo somatic hypermutation (SHM) and 
class switch recombination (CSR). SHM introduces single base-pair mutations in the 
variable region of the immunoglobulin gene. The resulting BCR mutants that have 
acquired increased antigen affinity, can successfully out-compete other B cells for 
access to limited antigen on follicular dendritic cells (FDCs) and signals mediated by T 
follicular helper (TFH) cells that sustain GC B cell responses. This process of affinity 
maturation continually selects for B cells with higher affinity BCRs. B cells that survive 
the GC reaction can terminally differentiate into either memory B cells capable of quickly 
responding to repeat antigen exposure or differentiate into PCs that secrete higher 
affinity antibodies of various isotypes through CSR9. 
The signals that initiate the differentiation of activated B cells into ASCs remain to 
be fully characterized. However, studies have shown that BCR affinity and intracellular 
signals delivered through the BCR and/or other ligands associated with FDCs may 
initiate differentiation10. In addition, metabolic reprogramming and mitochondrial 
remodeling have been shown to affect ASC differentiation and thus may contribute 
signals that initiate differentiation11, 12.  
 
ANTIBODY SECRETING CELLS 
The primary role of an ASC is to synthesize and secrete large amounts of 
antibodies. To perform this task, differentiating B cells expand their cytoplasm, 
endoplasmic reticulum (ER), and Golgi apparatus while also altering their metabolic, 
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cellular, and molecular programs. These adaptations require the coordinated change in 
the expression of hundreds of genes in a division dependent manner1, 13.  
At the transcriptional level, differentiation of activated B cells into ASCs requires 
reorganization of transcriptional networks and expression of distinct gene programs. B 
cell specifying transcription factors such as paired box gene 5 (PAX5) and B-cell 
lymphoma 6 (BCL6) are extinguished while ASC transcription factors such as PR-
domain containing protein 1 (BLIMP1), X box-binding protein 1 (XBP1), and interferon 
regulatory factor 4 (IRF4) are induced. These mutually exclusive factors maintain the 
clear distinctions between B cell and ASC identities14. BLIMP1 is the master regulator of 
ASC differentiation and is required for the establishment of the ASC gene expression 
program. Once established, however, the maintenance of the program is primarily 
BLIMP1 independent15. To support the synthesis and secretion of antibodies, BLIMP1 
and XBP1 regulate the unfolded protein response (UPR), a stress response pathway 
that ASCs and other secretory cells activate to respond to and alleviate ER stress 
generated by misfolded proteins15, 16. IRF4, facilitates ASC differentiation by repressing 
BCL6 and activating BLIMP1. It is also critical for PC survival, partly through the 
regulation of myeloid cell leukemia sequence 1 (MCL1), a key PC survival molecule15, 17, 
18. RNA binding proteins (RBPs), which post-transcriptionally regulate mRNAs are also 
involved in regulating B cell programs. As an example, knock-out of the RBP HuR, 
which regulates alternative splicing in activated B cells, inhibits mitochondrial 
metabolism and cell proliferation, thereby negatively affecting ASC differentiation19.  
ASCs must alter their metabolism to synthesize and secrete large quantities of 
antibodies. Quiescent B cells undergo low levels of glycolysis and moderate levels of 
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oxidative metabolism. Upon antigen stimulation through the BCR, glycolysis and 
oxidative metabolism are increased along with an increase in mitochondrial mass which 
helps the cell keep up with metabolic demands20, 21. Further, B cells stimulated with the 
TI antigen lipopolysaccharide (LPS), revealed that genes critical for oxidative 
metabolism were upregulated and required for PB differentiation22. Recent studies show 
terminally differentiated PCs actively import glucose and amino acids and rely on both 
glycolysis and oxidative metabolism for their bioenergetic needs. Additionally, the 
supply of amino acids appear to be partly regulated through BLIMP1 activation of 
several amino acid carriers such as CD9815. Further, ASCs must induce autophagy to 
generate metabolic substrates and to regulate sustainable antibody production to 
prevent cell death23.  
ASCs are broadly divided into short-lived and long-lived populations. PBs  
generated in the spleen from TI or TD extrafollicular responses are generally short-lived 
and do not survive past the contraction of the primary antibody response. These PBs 
are also referred to as short-lived PCs (SLPCs). PCs formed from GC reactions that 
migrate to the bone marrow are generally believed to be long-lived and are referred to 
as long-lived PCs (LLPCs)1. The bone marrow niche is made up of multiple cell types 
including mesenchymal stromal cells and eosinophils. Evidence shows that the bone 
marrow niche supports PC survival through cell-cell contacts and/or soluble signals from 
these cells24. LLPCs, however, localize to the spleen and other tissue types in the body 
following TI and TD immune responses and therefore are not confined to the bone 
marrow niche25, 26. Further, PCs of varying lifespans, are present in the bone marrow- 
one study suggesting that as many as 50% of bone marrow PCs are newly formed and 
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short-lived27. These studies reveal that access to survival niches and cell extrinsic 
factors are not the sole determining factors regulating ASC longevity25, 28.   
The simplest method to determine intrinsic factors and pathways that regulate 
longevity is to directly compare SLPCs with LLPCs. In mice, ASCs in the spleen and 
bone marrow are currently identified based on the surface expression of B220 and 
CD138. SLPCs have been identified as B220+CD138+ while LLPCs have been identified 
as B220-CD138+29. Human bone marrow ASCs are identified by the expression of 
CD19, CD27, CD38, and CD138 with SLPCs identified as CD19+CD38+ and LLPCs 
identified as CD19-CD38+30. Recently, Lam et al. used the fluorescently-labeled glucose 
analog 2NBDG to sort mouse CD138+ splenic and bone marrow PCs into subsets 
based on B220 expression and 2NBDG import. They found 2NBDG import could 
discriminate PCs of differing lifespans. RNA-sequencing of splenic PC subsets 
representing SLPCs and a bone marrow PC subset representing LLPCs failed to 
identify significant transcriptional changes that could account for lifespan differences. 
Major factors involved in ASC differentiation and survival, as well as UPR regulators 
and related transcripts, were not differentially expressed. Additionally, RNA-seq analysis 
of human bone marrow CD19- LLPCs and CD19+ SLPCs also found relatively little 
difference between the two subsets31. 
Although transcriptionally similar, mouse LLPCs from the bone marrow were 
found to be metabolically distinct from SLPCs from the spleen. LLPCs import more 
glucose compared to SLPCs, which is used primarily for antibody glycosylation and to 
sustain increased antibody secretion. Under bioenergetic stress, LLPCs are capable of 
diverting glucose away from glycosylation and shift it to glycolysis, using the resultant 
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pyruvate to increase oxidative metabolism and generate higher spare respiratory 
capacity (SRC). Mitochondrial SRC is the difference between the maximal and basal 
respiratory capacities. SRC has been correlated with enhanced cell survival and a 
reduction in SRC has been associated with cell death32. When pyruvate import was 
inhibited in LLPCs, oxidative metabolism was reduced to levels observed in SLPC 
levels and SRC was ablated. Further, deletion of the mitochondrial pyruvate carrier 2 
(Mpc2) gene in mouse B cells, resulted in the progressive loss of bone marrow PCs33.  
The lack of significant transcriptional differences may suggest that lifespan and 
longevity are not transcriptionally regulated. However, due to the heterogeneity of the 
ASC population in the spleen and bone marrow and an inability to purely sort PC 
subsets with differing half-lives, relevant but subtle transcriptional differences may be 
muted and masked34.  
 
CREB AND CRTCs 
 
 
The cyclic-AMP response element binding protein (CREB) is a ubiquitously 
expressed member of the basic leucine zipper (bZIP) transcription factor superfamily. 
Regulated through phosphorylation, cellular signals such as cAMP and Ca2+ flux 
promotes the phosphorylation of serine-133 (S133) in the kinase inducible domain of 
CREB. Phosphorylation at this residue, leads to CREB interaction with the histone 
acetyltransferase CREB binding protein (CBP) and the CBP paralog p300. Interaction 
with CBP/p300 activates transcription of CREB responsive genes by acetylating local 
histones and recruiting the transcriptional machinery. CREB binds to DNA through 
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recognition of an 8-base pair palindromic DNA binding motif known as a full cAMP 
response element (CRE) or a less active half CRE site in the promoter of genes35.  
 In the canonical CREB activation pathway, phosphorylation of CREB at serine-
133 (S133) is sufficient for its interaction with CBP/p300 and gene activation. However, 
CREB can also activate genes independently of S133 phosphorylation. A cDNA over-
expression screen identified the transducers of regulated CREB (TORC) as potent 
activators of CREB36, 37. TORC proteins were later renamed the CREB-regulated 
transcriptional coactivators (CRTCs) to not be confused with the mTOR signaling 
complexes. The CRTC family consists of three members (CRTC1-3) in mammals and a 
single functional homolog in D. melanogaster and C. elegans. CRTCs contain a 
conserved N-terminal CREB binding domain, a central regulatory domain, a splicing 
domain, and a C-terminal transactivation domain. CRTC2 and CRTC3 are ubiquitously 
expressed while CRTC1 is mainly expressed in the brain.  
CRTCs are negatively regulated through phosphorylation by AMP-activated 
protein kinase (AMPK) and AMPK family member proteins, which lead to their 
interaction with 14-3-3 proteins and cytoplasmic sequestration. Dephosphorylation of 
CRTCs by the serine/threonine phosphatase calcineurin leads to CRTC activation by 
triggering its nuclear re-localization and binding to CREB35. The list of CREB-dependent 
CRTC targets reveal that the CREB-CRTC signaling axis is important for regulating 
global energy homeostasis38. Beyond transcriptional regulation, CRTCs have been 
implicated to have a role in alternative splicing. Although CRTCs lack recognizable RNA 
binding domains, in-vitro splicing assays revealed that CRTCs could regulate alternative 
exon usage and 3’ splice-site selection independently or coupled with their gene 
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activation function. In addition, the CRTC1/MAML2 (mastermind-like protein 2) fusion 
oncogene which induces mucoepidermoid carcinomas, results in the deletion of the 
splicing domain of CRTC1. When tested for splicing activity in vitro, CRTC1/MAML2 
negatively affected splicing when compared to full-length CRTC139. However, CRTCs 
have yet to be shown to regulate mRNA alternative splicing in a physiologically relevant 
system. 
 
CRTC2 
 
 CRTC2 is abundantly expressed in the liver, spleen, and lymph nodes and has 
been extensively studied for its role in glucose homeostasis. In hepatocytes, the release 
of glucagon induces CRTC2 activation and CREB regulated transcription of 
gluconeogenic enzymes that promote glucose output40. In vitro kinase assays showed 
that the AMPK family member proteins salt inducible kinase 2 (SIK2) and microtubule 
affinity regulating kinase 2 (MARK2) phosphorylate CRTC2 at serine-171 (S171) and 
serine-275 (S275), respectively. Inhibition of phosphorylation at each of these residues 
through serine to alanine mutations retain CRTC2 in the nucleus while a double mutant 
containing S171A and S275A (CRTC2-AA) results in the complete nuclear localization 
and constitutive activation of CRTC241, 42.  
Work on the role of CRTC2 in lymphocyte biology is limited. In T cells, the CREB-
CRTC2 pathway was shown to regulate IL-17 expression. In a CRTC2 knock-out mice, 
CRTC2 mutant T cells expressed lower levels of IL-17 and exhibited impaired Th17 cell 
differentiation43. Also in T cells, CRTC2 functions to preserve genome integrity as the 
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loss of CREB and CRTC2 was found to reduce the expression of mismatch repair 
genes, which resulted in increased mutation frequencies in various T cell lymphomas44.  
Our laboratory previously described a signaling pathway that linked DNA double 
strand breaks associated with CSR to the inactivation and cytoplasmic localization of 
CRTC2 in human GC B cells. DNA damage triggers the activation of the DNA damage 
sensor ataxia-telangiectasia mutated (ATM), which signals through liver kinase B1 
(LKB1) and to an AMPK family member protein which phosphorylates CRTC2. 
Activation of this signaling pathway promotes GC exit and ASC differentiation of human 
B cells by down-regulating CRTC2 target genes45. In addition, we have shown that BCR 
signaling can also inactivate CRTC2 and down-regulate its target genes in GC B cells45, 
46. When CRTC2 inactivation was dysregulated through the expression of the 
constitutively active CRTC2-AA mutant, stimulated B cells maintained expression of 
CRTC2 target genes which resulted in maintenance of GC markers and increased 
proliferation. Consequently, the expression of the ASC marker Prdm1 (BLIMP1) along 
with antibody secretion was inhibited compared to control B cells45. Therefore, we 
speculated that CRTC2 inactivation initiated by CSR in the GC may potentially function 
as a physiologic trigger that initiates ASC differentiation. However, it remains unknown 
when CRTC2 inactivation is critical for ASC formation because activation, proliferation, 
and PC differentiation are plausible regulatory nodes. Additionally, whether CRTC2 
plays a critical role in ASC formation in vivo has not been investigated. 
  
This dissertation aims to address the gaps in our understanding of the in vivo role 
of CRTC2 in B cell differentiation and to determine its effects on the generation and 
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maintenance of long-term humoral immunity. Additionally, this work may provide 
insights into augmenting antibody responses and providing potential therapeutic targets 
to inhibit ASCs that generate pathogenic antibodies. 
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Abstract 
Antibody secreting cell (ASC) function and longevity determines the strength and durability of a 
humoral immune response. Using transgenic (TG) mice that express a constitutively active form 
of the CREB coactivator CRTC2 (Crtc2-AA), we demonstrate that Crtc2 repression in plasma 
cells (PCs) is an intrinsic requirement for ASC metabolic fitness. Sustained CRTC2 activity 
shortens the survival of splenic and bone marrow PCs, resulting in reduced numbers of long-
lived PCs and antibody deficits against T-dependent and T-independent antigens, and an acute 
viral infection. TG PCs adopt a short-lived PC phenotype as shown by reduced antibody 
secretion, glycolysis, oxidative metabolism, and spare respiratory capacity. Mechanistically, 
Crtc2 repression is necessary for the fidelity of PC gene expression and mRNA alternative-
splicing programs, with both programs altered in TG PCs. Combined, Crtc2 repression in PCs 
must occur to support PC metabolism and extend ASC survival and lifespan during a humoral 
immune response.   
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Introduction 
In secondary lymphoid tissues, B cell activation in response to certain antigens can result in the 
rapid differentiation of transient plasmablasts (PBs) that localize to extrafollicular regions and 
mature into predominantly short-lived plasma cells (SLPCs). These antibody secreting cells 
(ASCs) typically produce an initial wave of low-affinity antigen-specific antibodies1. In 
comparison, primary follicular B cells activated by a T cell dependent (TD) antigen at the T:B 
border zone can rapidly expand within B cell follicles to form germinal centers (GCs). GC B cells 
undergo both extensive proliferation and antigen-driven affinity maturation resulting in the 
formation of plasma cells (PCs) that secrete high-affinity isotype-switched antibodies. These 
cells can then migrate to the bone marrow and become long-lived PCs (LLPCs)2. Antibody 
quality and the duration of antibody production are major determinants of protection against 
target pathogens and maintenance of long-term humoral immunity3. Unfortunately, the 
production of pathogenic PCs can also generate autoantibodies that participate in a range of 
autoimmune disorders4. Identifying factors that regulate PC differentiation, function, and survival 
could improve vaccine design and uncover potential strategies to eliminate the production 
and/or maintenance of pathogenic PCs. 
To generate ASCs, extensive epigenetic, transcriptional, and metabolic remodeling must 
occur to terminate B cell and GC B cell specification and maintenance programs, coupled with 
induction of ASC differentiation5, 6, 7. Differing in their ontogeny, localization, function, and 
lifespan, ASCs are present as a heterogenous and diverse population. RNA expression profiling 
of splenic PCs that are enriched for SLPCs and bone marrow PCs that are enriched for LLPCs 
failed to identify wholesale transcriptional changes that could explain phenotypic differences in 
SLPC and LLPC longevity8. Instead, LLPCs were shown to develop a unique metabolic program 
that results in enhanced glucose import as well as increased pyruvate utilization for 
mitochondrial oxidative metabolism during times of stress9. How this metabolic program is 
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initiated and maintained in LLPCs is currently unknown. The lack of candidate gene expression 
differences between SLPCs and LLPCs that underlie differences in survival or longevity may 
suggest non-transcriptional or extrinsic factors. However, because of heterogeneity in the ASC 
population, meaningful mRNA transcript differences may actually exist that are muted within this 
heterogeneity and therefore overlooked.  
Identified over a decade ago, a family of three cAMP response element binding protein 
(CREB)-regulated transcription coactivators (CRTC1 – 3) control gene expression and several 
additional biological processes10, 11, 12. Extracellular and intracellular signals phosphorylate 
CRTC family proteins, which influences their subcellular localization13, 14. CRTC proteins lacking 
phosphorylation at specific residues localize in the nucleus where they can bind to CREB and 
additional bZIP transcription factors to regulate gene expression for processes such as energy 
homeostasis, metabolism, and lifespan11, 12. Previously, we showed that CRTC2 
phosphorylation in an in vitro B cell differentiation model caused CRTC2 inactivation by 
cytoplasmic re-localization, which triggered B cells to lose their GC-like identity and differentiate 
into ASCs15. Using isolated B cells, DNA damage during immunoglobulin (Ig) class switch 
recombination (CSR) initiated a signaling cascade involving ATM, LKB1, and an AMPK family 
member protein that phosphorylated and inactivated CRTC2 to down-regulate its gene 
regulatory network. Failed CRTC2 inactivation caused GC B cell biomarkers to remain elevated 
and inhibited ASC biomarker acquisition and antibody secretion. However, it remains unknown 
when CRTC2 inactivation is critical for ASC formation because activation, proliferation, and PC 
differentiation are plausible regulatory nodes. Additionally, whether CRTC2 plays a critical role 
in ASC formation in vivo has not been investigated. 
To examine CRTC2 in B cell physiology, we generated transgenic (TG) mice that 
express constitutively active, nucleus-localized CRTC2 throughout B cell development.  Here, 
we report on this unique CRTC2 TG mouse model and the unexpected result that CRTC2 
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inactivation in PCs is required for ASC survival, yielding at least a partial mechanism to explain 
the longevity of the humoral immune response.  
Results 
Crtc2 expression in B cells is repressed during PC differentiation. Initially, we examined 
the expression of CRTC2 in isolated, naïve splenic B cells from wild-type (WT) C57BL/6 mice 
stimulated with CD40L and IL-4, conditions that resemble a TD immune response16, 17. At early 
timepoints post-stimulation, CRTC2 lacked phosphorylation. By 24h post-stimulation, 
approximately half of the CRTC2 protein was phosphorylated, followed by a progressive 
reduction of total CRTC2 protein through day 5 of stimulation (Fig. 1a). Consistent with 
progressively reduced CRTC2 protein, Crtc2 mRNA expression was repressed over the 
differentiation assay time course (Fig. 1b). At day 5, when CRTC2 expression was at its lowest, 
we observed the robust differentiation of activated B cells into B220- CD138+ PCs as identified 
by flow cytometry (Fig. 1c). Additionally, we observed a 6-fold induction of Prdm1, encoding the 
ASC master regulator protein BLIMP1, in this bulk differentiation assay (Fig. 1d). These results 
show that CRTC2 inactivation by protein phosphorylation and transcriptional repression occurs 
during the transition from early B cell activation through PC formation.    
 
Generation of an in vivo model to study Crtc2 repression in PCs. To study potential roles 
for CRTC2 in mature B cells in vivo, we generated a TG mouse model that expresses a 
nucleus-localized, constitutively active form of CRTC2, generated with S171A and S275A amino 
acid substitutions in the transgene (Crtc2-AA)14, 15, 18. The Crtc2-AA transgene is under B29 (Igb) 
minimal promoter and IgH intronic enhancer (Eµ) control (Supplementary Fig. 1a). Previously, 
we showed that this promoter-enhancer combination enables transgene expression from pro-B 
through PC stages of B cell differentiation19, 20. Three founder mice were generated with a range 
of Crtc2-AA transgene expression. Two founder lines (F2 and F3) reproducibly showed 3-fold 
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higher levels of Crtc2-AA expression in the bone marrow than the third founder line (F1) 
(Supplementary Fig. 1b). We analyzed bone marrow B lymphocyte development using flow 
cytometric analysis of the cell surface markers B220, CD43, and IgM. Founder line F1, with 
modest total (endogenous and transgene) Crtc2 overexpression in the bone marrow (1.4-fold 
compared to WT) (Fig. 2a), demonstrated normal production of pro-B (B220+ IgM- CD43+), pre-
B (B220+ IgM- CD43-), immature (B220+ IgM+), and mature B220hi IgM+ B lymphocytes 
compared to WT mice (Fig. 2b). In contrast, founders F2 and F3 demonstrated a significant 
reduction in bone marrow B lymphopoiesis (Supplementary Fig. 1c). While interesting, F2 and 
F3 founder lines were not examined further because of this impairment in early B cell 
development. F1 lineage mice showed total Crtc2 expression that was 3.4-fold higher in the 
spleen compared to WT mice (Fig. 2a), and F1 lineage spleens possessed similar total 
numbers of follicular (B220+ CD19+ CD23+ CD21-) and marginal zone (B220+ CD19+ CD23- 
CD21+) B cells as WT controls (Fig. 2c). Finally, low level Igb (encoded by B29) expression was 
reported in early thymocyte development21. However, total Crtc2 expression was not 
significantly increased in F1 thymocytes (Fig. 2a) and T lineage cell numbers in F1 thymus and 
spleen were similar to WT controls (Fig. 2d,e). Thus, B and T cell development appeared 
similar between F1 TG and WT mice.  
To exclude transgene insertion site issues in F1 lineage mice, we performed whole 
genome sequencing and identified two distinct Crtc2-AA genome integration sites. One 
integration site was in a region of the mouse genome lacking any genes and the second site 
was in a large intronic region of a gene (1110051M20Rik) with no functional annotation 
(Supplementary Fig. 1d). This second transgene integration had no affect on the expression of 
the annotated gene as determined by RNA sequencing (RNA-seq) of TG and WT B cells 
(Supplementary Table 1). 
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Next, we examined the level of Crtc2 expression in activated B cells. We stimulated 
naïve, isolated splenic B cells with CD40L, IL-4, and IL-5 for 5 days to increase the number of 
PCs obtained17. On day 5, stimulated B cells were sorted into early division (0-3), late division (5 
or more), and PC subpopulations based on CFSE dye dilution and expression of the ASC cell 
surface marker CD13822 (Supplementary Fig. 1e). We further validated the identity of our in-
vitro derived and sorted PCs by comparing expression profiles to in vivo derived PC gene 
signatures22 (data not shown). RNA-seq of naïve B cell controls and sorted, stimulated B cell 
subpopulations revealed stable endogenous Crtc2 expression in naïve, early, and late division B 
cell subsets, along with robust Crtc2 repression in WT PCs (Supplementary Fig. 1f). By 
contrast, Crtc2-AA TG B cells showed minimally elevated total Crtc2 expression in naïve and 
early division B cell subsets, with 1.4-fold and 4.4-fold increased expression in late division and 
PC subpopulations, respectively (Supplementary Fig. 1f). Induced expression of total Crtc2 in 
TG PCs is consistent with increased enhancer activity known to elevate Ig gene expression at 
the PC stage of B cell differentiation23. These data validate our Crtc2-AA TG model that 
replicates expected transgene expression throughout B cell differentiation and provides 
sustained, over-expressed Crtc2-AA transcripts specifically in PCs, the stage in differentiation 
where endogenous Crtc2 is strongly repressed.  
 
CRTC2 repression enables PC survival and humoral immune responses. Our prior in vitro 
studies showed that aberrantly sustained CRTC2 activity following B cell activation caused a 
defect in ASC differentiation15. However, this pure B cell model left open the key question about 
the main role(s) for CRTC2 repression during an in vivo immune response. Analysis of the ASC 
population in naïve unimmunized mice revealed a significant decrease in the splenic PC 
population, while the PB population was unaffected in TG mice compared to WT controls (Fig. 
3a). Further analysis of the serum of naïve mice revealed lower Ig titers in TG compared to WT 
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mice for all isotypes, except for IgA (Fig. 3b). Next, we immunized mice with TNP-Ficoll to 
induce a T cell independent (TI) immune response. TNP-specific IgM titers in the serum were 7-
fold lower in TG compared to WT mice 7 days post-immunization (Fig. 3c). Mice were also 
immunized with NP-CGG in alum to induce a TD immune response. At 14 days post-
immunization, NP-specific IgM and IgG1 titers were 2.7- and 6-fold lower in the serum of TG 
compared to WT mice, respectively (Fig. 3d). At 35 days, NP-specific serum IgG1 levels 
remained significantly lower in TG compared to WT mice, revealing that reduced Ig levels are 
not due to slower ASC differentiation in TG B cells (Fig. 3d). We also infected mice with the 
acute Armstrong strain of lymphocytic choriomeningitis virus (LCMV) to analyze the antiviral B 
cell response. This viral strain produces a vigorous T cell response that clears the infection 8 – 
10 days post-infection but also elicits a robust TD B cell response, which generates LLPCs24, 25. 
Analysis of the spleen 8 days post-infection revealed a sharp reduction in the percentage of 
PCs in TG mice (Fig. 3e), along with a marked reduction in Ig titers for both total and LCMV-
specific IgG compared to WT control mice (Fig. 3f,g). 
We then performed ELISPOT assays to enumerate ASC frequencies, where each spot 
within an assay well represents an ASC whose spot intensity and/or size indicates the amount 
of antibody secreted. Consistent with reduced splenic PC numbers in naïve mice and reduced 
Ig titers, splenic ASCs generated from TI immunizations were reduced over time in TG 
compared to WT mice (Supplementary Fig. 2a,b). Of note, although there is no statistical 
difference in ASC numbers at day 7, a difference in spot intensities, with blue spots being most 
intense, was detected between WT and TG ASCs (Supplementary Fig 2a,b). By day 14 
however, only blue spots are left remaining, resulting in a reduction in splenic ASCs in TG 
compared to WT mice (Supplementary Fig 2a,b). In ASCs generated from a TD response, 
there was also a dependence on time and spot intensity in ASC results. IgM specific ASCs were 
reduced in number from the spleen of TG compared to WT mice (Supplementary Fig. 2c,d).  
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For IgG1-secreting ASCs however, although statistically similar in number between TG and WT 
mice, TG IgG1 ASCs exhibited less intense spots than WT IgG1 ASCs (Supplementary Fig. 
2c,d). For more mature ASCs, those representing PCs that have migrated into the bone 
marrow, both IgM- and IgG1-secreting PCs were reduced in number in TG compared to WT 
mice (Supplementary Fig. 2e,f). Interestingly, a recent report showed that LLPCs imported 
more glucose and secreted more antibodies than SLPCs, linking antibody secretion levels to 
length of PC survival9, 26. Observations of spots with varying intensities indicated heterogeneous 
populations of ASCs with different levels of antibody secretion and potentially different levels of 
glucose import. Thus, the data show that CRTC2 inactivation and repression in PCs supports 
the function and maintenance and by extension, possibly the length of PC survival.  
To determine whether sustained Crtc2-AA expression effects were cell intrinsic, isolated 
naïve splenic B cells were activated in vitro with CD40L, IL-4, and IL-5. A time-course analysis 
of PC formation and/or persistence revealed that the reduction in ASC numbers and humoral 
immune responses were cell intrinsic, as TG PCs decreased over the course of stimulation, 
ending with a reduction from 37.3 to 18.4 percent PCs at day 5 (Fig. 3h). The decrease in TG 
compared to WT PCs is not related to changes in B cell activation, proliferation, GC formation, 
or CSR during B cell differentiation (Supplementary Fig. 3). Instead, we found that CRTC2 
inactivation supported the survival of B cells in an advanced stage of differentiation, as the 
number of stimulated TG B cells were reduced in a division dependent manner compared to WT 
controls (Fig. 3i). Quantification of cell numbers by flow cytometry gating on early divisions, late 
divisions, and PC subpopulations revealed a significant decrease in cell numbers only for PCs, 
indicating that the difference in cell death occurs at a differentiation stage where CRTC2 is 
markedly repressed but is instead sustained in active form by the Crtc2-AA transgene 
(Supplementary Fig. 1f and Fig. 3j). Consistent with increased cell death detected by flow 
cytometry, immunoblot analysis with band densitometry also showed an increase in expression 
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of the pro-apoptotic biomarkers cleaved PARP and cleaved caspase-3 in TG compared to WT 
stimulated B cells (Fig. 3k). With the loss of in vitro generated PCs (Fig. 3h) and a reduction in 
splenic and bone marrow ASCs over time (Supplementary Fig. 2), TG PCs exhibit an intrinsic 
survival defect. Thus, physiologic CRTC2 inactivation and repression is required for PC survival 
in the spleen and bone marrow, directly affecting the generation of a robust, long-lived 
(Supplementary Fig. 2) humoral immune response.  
 
CRTC2 regulates mature B cell mRNA transcription and splicing. To gain insight into 
reduced PC survival with sustained Crtc2-AA expression, we performed RNA-seq on naïve and 
sorted early division, late division, and PC TG and WT B cell subpopulations (Supplementary 
Fig. 1e). Principle-component analysis (PCA) of the RNA-seq data showed that each replicate 
within a given subpopulation clustered together, as expected, and that TG and WT B cell 
subsets were similar until modest separation occurred in the PC subpopulation (Fig. 4a). In 
concordance, Crtc2-AA induced the largest number of transcript differences for TG versus WT 
cells at the PC stage, with 767 differentially expressed genes (p-adj < 0.05). Most differential 
genes were up-regulated (502/767, 65%), consistent with the established role of CRTCs as 
transcription coactivators (Fig. 4b, Supplementary Table 1)11. By contrast, 38, 54, and 26 
genes were differentially-expressed in naïve, early division, and late division subpopulations, 
respectively (p-adj < 0.05) (Fig. 4b, Supplementary Table 1). Of the differentially-expressed 
genes within the PC subpopulation, 192 had >|2|-fold (Log2 fold > |1|) changes in expression 
(Fig. 4c). Key regulators of B cell fate and survival, such as Prdm1, Irf4, and Mcl1 showed no 
significant differences in TG compared to WT PCs 22, 27, 28, 29 (Fig. 4d). However, Cd28, a 
costimulatory protein expressed in activated T cells and ASCs, was repressed 2.6-fold in TG 
compared to WT PCs30, 31, 32 (Fig. 4d). CD28 regulates mitochondrial metabolism in T cells and 
while being a pro-survival factor for LLPCs in the bone marrow, is dispensable for the survival of 
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splenic SLPCs33. Gene set variation analysis (GSVA) also showed no differences between TG 
and WT subpopulations for BLIMP1 and IRF4 target genes, unfolded protein response (UPR) 
genes, and canonical early activation, GC, and ASC gene signatures (Fig. 4e) 27, 29. In addition, 
analysis of all Ig transcripts between TG and WT B cell subpopulations were similar, indicating 
that the observed reduction in Ig secretion in TG ASCs by ELISPOT assay was not from 
changes in transcript levels (Supplementary Table 1).   
To identify candidate biological processes influenced by CRTC2 in PCs, we examined 
differentially expressed genes in the PC subpopulation by KEGG pathway analysis. The top 
three significantly enriched pathways were DNA replication, cell cycle, and spliceosome genes 
(Fig. 4f). Recent reports show a role for alternative splicing in B cell fate, prompting an 
assessment of CRTC2 in alternative splicing during B cell differentiation34, 35, 36, 37. CRTCs do not 
contain conserved RNA binding domains, although one in vitro study in non-immune cells 
suggests that CRTCs may regulate mRNA splicing11, 38. It remains unknown, however, whether 
CRTC2 impacts mRNA splicing in activated B cells maturing into PCs. Analysis of the RNA-seq 
data revealed significant alterations (by >10%) in the splicing of 604 TG versus WT genes, most 
of which occurred in the PC subpopulation that favored skipped exons (SE) (Fig. 4g and 
Supplementary Table 2). Of note, only 33 (2.3%) of gene transcripts were altered by both 
expression and splicing between TG and WT B cells (Fig. 4h). Alternatively spliced genes were 
enriched for those that modify histones, contain methyltransferase activity, and those involved in 
organelle biogenesis (Fig. 4i). Genes including Cep89, Ndufaf7, and Sirt3 have known roles in 
regulating mitochondrial metabolism while epigenetic modifiers such as Dnmt3b regulate B cell 
differentiation39, 40, 41, 42. Thus, CRTC2 independently regulates gene expression and mRNA 
splicing and its repression mediates the fidelity of these processes at the PC stage of B cell 
differentiation.   
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Crtc2 repression increases oxidative metabolism. CRTCs have established roles in energy 
homeostasis and mitochondrial metabolism 43, 44 and our data shows that CRTC2 controls 
mRNA expression and splicing associated with mitochondrial metabolism (e.g. Cd28, Cep89, 
Ndufaf7, Sirt3 transcripts) in PCs. A selective GSVA for metabolism regulating genes revealed 
that TG PCs show a metabolic gene expression profile similar to late dividing WT and TG PC 
precursors that clustered distinctly from WT PCs (Fig. 5a). To determine whether TG and WT 
PCs were metabolically distinct, we measured the cellular oxygen consumption rate (OCR) and 
extracellular acidification rate (ECAR) as surrogates for mitochondrial respiration and glycolysis 
using a Seahorse Extracellular Flux Analyzer. OCR measurements on sorted in vitro derived 
CD138+ PCs revealed similar basal respiration with reduced maximal respiration and reduced 
spare respiratory capacity (SRC) for TG compared to WT PCs (Fig. 5b,c,d,e). Cells utilize SRC 
during conditions of increased work or stress and LLPCs show increased SRC45. Interestingly, 
suppressed pyruvate generation and/or mitochondrial pyruvate import also reduces SRC, which 
leads to progressive loss of LLPCs in the bone marrow9. ECAR measurements in TG PCs also 
trend lower than the WT control, suggesting less available pyruvate for glycolysis or oxidative 
metabolism (Fig. 5f).  
Consistent with reduced ECAR, steady-state metabolomics of bulk day 5 in vitro 
stimulated TG and WT B cells showed a decrease in the glycolytic metabolites fructose 1,6-
bisphoshate (F16BP) and dihydroxyacetone phosphate (DHAP), and a reduction in the end 
product of the hexosamine biosynthetic pathway, UDP-GlcNAc, which is required for Ig 
glycosylation (Fig. 5g). TG B cells also showed an increase in a-ketoglutarate and succinate 
compared to WT PCs (Fig. 5g). These data indicate that CRTC2 repression is required for 
increased oxidative metabolism and may regulate metabolic pathway activities in PCs, which 
could impact PC survival and function.  
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Discussion 
Our results demonstrate the requirement for physiologic Crtc2 repression in PCs in order to 
maintain a humoral immune response. Elevated expression of a Crtc2-AA transgene at this 
stage in differentiation reduced the survival of PCs, resulting in humoral immune deficits against 
model antigens and an acute viral infection. Differentiation into PBs, however, is unaffected by 
CRTC2-AA, as naïve TG mice have similar numbers of splenic PBs as WT mice. In addition, 
similar numbers and frequencies of ASCs generated by immunizations and in vitro 
differentiation, respectively, at early timepoints further shows that the defect in survival lies 
within the more mature PC population. Our results were not specific to a particular type of 
immune stimulus as both TI and TD immune responses required the inactivation of CRTC2 for 
establishment of the mature PC pool. This suggests a generalized and critical need to suppress 
CRTC2 to generate PCs regardless of eliciting antigen. Perhaps this is not surprising as both TI 
and TD responses have been shown to generate LLPCs in the bone marrow46. 
The metabolic requirements of PCs differ from those of activated B cells and 
differentiating PBs. Instead of using energy and biosynthetic pathways for nucleotide synthesis 
and organelle biogenesis, PCs switch their metabolism to support antibody production7. 
Interestingly, our studies showed that repression of Crtc2 in PCs is necessary for fidelity of PC 
gene expression and mRNA alternative-splicing programs. When these processes are altered 
by sustained CRTC2-AA activity, TG PCs show reductions in antibody secretion, glycolysis, 
oxidative phosphorylation, and SRC essentially adopting a SLPC-like phenotype26. Combined, 
the data suggest that CRTC2, and/or its affected non-overlapping gene and splicing targets, 
control metabolic programs required for mature PC survival and establishment of LLPCs in the 
bone marrow to sustain a long-term humoral immune response. 
CD28, which is expressed in PCs and is critical for LLPC survival, is repressed nearly 
2.6-fold in TG PCs33. In T cells, CD28 activation establishes SRC and increases glycolysis and 
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oxidative phosphorylation in memory T cells47. Similar phenotypic effects observed in WT PCs 
may suggest that CD28 controls similar functions in PCs to regulate LLPC survival. Reduced 
oxidative phosphorylation in TG PCs may also be associated with a 2-fold reduction in the 
expression of Aldoc, a key glycolytic enzyme necessary for generating mitochondrial pyruvate. 
TG PCs show a 3.5-fold over-expression of the solute carrier Slc1a2, which has high affinity for 
glutamate. In addition, Glud1, the mitochondrial glutamate dehydrogenase that converts L-
glutamate into a-ketoglutarate, is aberrantly spliced in TG PCs.  These changes imply that 
reduced pyruvate generation through the glycolytic pathway in TG PCs is partially compensated 
through glutamine anaplerosis with incomplete recovery of respiration as shown by our OCR 
studies. TG PCs also aberrantly splice mRNA transcripts compared to WT PCs that associate 
with electron transport chain (ETC) complex activity and formation, suggesting that alterations in 
ETC activity may also contribute to impaired oxidative phosphorylation and reduced SRC in TG 
PCs, which would inhibit the previously demonstrated metabolic changes required to generate 
LLPCs. 
Based on reductions in survival, antibody secretion, glycolysis, and oxidative 
phosphorylation in TG ASCs, we speculate that WT SLPCs might express more Crtc2 
transcripts than WT LLPCs because of strong similarities to the Crtc2-AA mouse model. 
Consistent with this prediction, independent RNA-seq profiling of PC subsets with different half-
lives26 showed highest Crtc2 expression in the shortest half-life PC subset and the lowest 
expression in the longest half-life PC subset (Fig. 6a). Unfortunately, this data mining difference 
in Crtc2 mRNA transcripts trended but was not statistically significant between PC subsets. Of 
note, the PC subsets analyzed were not pure populations because of current technical 
limitations in identifying PC heterogeneity and isolating these populations, and thus may 
account for the lack of statistical significance in Crtc2 expression despite a clear trend 26. Our 
prior signaling studies showed that CRTC2 inactivation by phosphorylation and cytoplasmic re-
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localization in B cells initiates through engagement of the B cell antigen receptor (BCR) and/or 
through DNA double-stranded breaks during IG CSR15, 48. These prior results, coupled with 
reduced Crtc2 expression during PC generation shown here, yields a conceptual framework in 
which the level of CRTC2 activity in PCs helps to establish a metabolic profile supporting PC 
function and longevity through numerous, modest but essential effects on gene expression and 
mRNA transcript splicing (Fig. 6b). 
In prior studies, we showed that CRTC2-AA over-expression in isolated and stimulated 
human B cells blocked ASC differentiation by maintaining activated B cells in a GC-like state. 
The difference in outcome between those results and our report here may relate to differential 
biological functions of CRTC2 at different stages of B cell development. This is similar to BCL6, 
which regulates self-renewal in pre-B cells but functions to regulate survival in GC B cells49. We 
speculate that when CRTC2-AA expression is enforced in early activated human B cells, ASC 
differentiation is blocked, whereas enforced CRTC2-AA expression in mouse PCs results in 
altered metabolism and a survival defect. Interestingly, IRF4, which also has multiple roles in B 
cells29, 50, was recently shown to be required in PCs to maintain mitochondrial homeostasis; 
providing a potential explanation for the requirement for IRF4 in PC survival51. In our TG model, 
the major ASC transcriptional regulators including IRF4 are unaffected, suggesting that factors 
downstream or independent of these major regulators are necessary to regulate PC 
metabolism.  
Although discovered over a decade ago, new roles in physiology and disease are being 
attributed to the CRTC family12, 43. Our study shows that Crtc2 repression is critical for PC 
function, survival, and lifespan. The impact of CRTC2 activity on PC metabolism and its role in 
regulating ASC survival and longevity may open new avenues for modulating humoral immune 
responses.  
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Methods 
 
Reagents, antibodies, and oligonucleotides 
This information is provided in Supplementary Table 4. 
 
Mice and animal procedures 
Crtc2-AA transgenic mice were derived by pronuclear injection of C57BL/6 mouse embryos at 
the UCLA and UCI transgenic mouse facilities. Briefly, the mouse Crtc2 coding sequence with 
introduced S171A and S275A alterations was cloned into a B29 minimal promoter, IgH intronic 
enhancer (Eµ) expression plasmid20. The plasmid was injected into the pronucleus of mouse 
embryos and then implanted in a surrogate dam for gestation. F0 generation pups were 
selected for transgene integration through tail biopsy and PCR analysis and three founder lines 
were identified. For in vivo experiments, mice were immunized by intraperitoneal administration 
of 2 x 108 sheep red blood cells (Colorado Serum Company), 25 ug of 2,4,6-Trinitrophenyl 
(TNP)-aminoethylcarboxymethyl-ficoll (AECM-Ficoll) (Biosearch Technologies), or 50 ug of 
alum-precipitated 4-Hydroxy-3-nitrophenylacetyl (NP)-chicken gamma globulin (CGG) 
(Biosearch Technologies). For viral infections, mice were inoculated intravenously with 2 x 106 
plaque forming units of the LCMV Armstrong strain. Virus stocks were prepared and viral titers 
were quantified as described52. Mouse experiments were conducted on mixed-sex mice 
between 8-12 weeks of age. No animals were excluded due to a lack of responsiveness to 
immunization or infection. Randomization, but not experimental blinding to sample identity was 
used for these studies. All animals were housed in a pathogen-free animal facility at UCLA and 
all procedures were performed with approval from the UCLA Animal Research Committee 
(#1998-113-63). 
 
Enzyme-linked immunosorbent (ELISA) & enzyme-linked immunospot (ELISPOT) assays 
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Serum Ig and TNP- and NP-specific antibodies were detected by ELISA as described53. TNP- 
and NP-specific ASCs were detected by ELISPOT assay. Briefly, MultiScreen HTS-HA filter 
plates (Millipore) for ELISPOT assays were prepared with 35% ethanol and then coated 
overnight at 4 °C with TNP-BSA or NP-BSA (Biosearch Technologies). Plates were washed and 
subsequently blocked at 37 °C with complete culture media prior to plating and culturing 
splenocytes or bone marrow cells for 18 h at 37 °C. Plates were washed with PBS-Tween 
(0.05%) and double-distilled water to remove cells before being incubated with alkaline 
phosphatase-conjugated anti-mouse IgM or anti-mouse IgG1 (Southern Biotech) for 2 h at room 
temperature. Plates were then washed with PBS-Tween (0.05%) and PBS before developing 
with BCIP/NBT blue substrate (Southern Biotech). Spots were imaged with an ImmunoSpot 
Analyzer (Cellular Technologies Ltd.) and quantified using ImageJ. 
 
B cell isolation and cell culture  
Whole spleens were mechanically disassociated through a 40 µm filter followed by red blood 
cell lysis with ammonium-chloride-potassium lysing buffer. Naïve mature B cells were isolated 
from spleen cells by immunomagnetic negative selection with anti-CD43 (Miltenyi Biotec). B 
cells were cultured in RPMI-1640 medium (Corning) supplemented with 10% FBS (Gibco), 1% 
penicillin/streptomycin (Corning), 1% MEM non-essential amino acids (Gibco), 1% sodium-
pyruvate (Corning), 1% L-glutamine (Gibco), and b-mercaptoethanol (50 µM). B cells were 
stimulated with 1 ug/ml CD40L (BD Pharmingen) and 25 ng/ml IL-4 (R&D Systems) or with 0.1 
ug/ml CD40L, 10 ng/ml IL-4, and 5 ng/ml IL-5 (R&D Systems) to monitor B cell processes during 
B cell differentiation or to monitor differentiation with increased plasma cell (PC) frequency, 
respectively22. For isolation of in vitro generated PCs, cultures stimulated for 5 days with 
CD40L, IL-4, and IL-5 were enriched for live cells using a dead cell removal kit (Miltenyi Biotec) 
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followed by CD138-APC (BD Pharmingen) staining. CD138+ PCs were enriched by positive 
immunomagnetic enrichment of APC (Miltenyi Biotec).   
 
Flow cytometry 
Single cell suspensions were stained with conjugated antibodies and data were obtained on a 
BD LSR II (BD Biosciences) and analyzed with FlowJo software (Treestar). Cell sorting was 
performed on a BD FACSAria (BD Biosciences). B and T cell populations, B cell class-
switching, and B cell activation were analyzed with anti-B220, anti-IgM, anti-IgG1, anti-CD4, 
anti-CD8, anti-CD19, anti-CD21, anti-CD23, anti-CD25, anti-CD43, anti-CD69, anti-CD86, anti-
CD93, anti-CD95(FAS) anti-CD138, and anti-GL7 (Supplementary Table 4). Cell populations 
analyzed were as follows: pro-B cells, B220+IgM-CD43+; pre-B cells, B220intIgM-CD43-; 
immature B cells, B220intIgM+CD43-; mature B cells, B220hiIgM+CD43-; follicular B cells, 
B220+CD19+CD93-CD23+CD21-/int; and marginal zone B cells, B220+CD19+CD93-CD23-CD21+; 
germinal center B cells, B220+GL7+CD95+; plasmablast (PB), B220+CD138+; plasma cell (PC), 
B220-CD138+; double negative T cells (DN), CD19-CD4-CD8-; double positive T cells (DP), 
CD19-CD4+CD8+; CD4 T cells, CD19-CD4+; and CD8 T cells, CD19-CD8+. Representative flow 
cytometry gating strategies are provided in Supplementary Fig. 4. DAPI was used for 
assessment of cell viability and in vitro B cell proliferation was assessed by flow cytometry after 
labeling of isolated CD43- naive mature B cells with CellTrace carboxyfluorescein succinimidyl 
ester (CFSE) (Invitrogen).  
 
Protein separation and immunoblot analysis  
Total whole cell extracts were prepared by incubating cells in lysis buffer containing 50 mM Tris 
HCl pH 7.4, 100 mM NaCl, 1 mM EDTA, and 1% Triton X-100 supplemented with protease and 
phosphatase inhibitors (Sigma Aldrich). Cell extracts were quantified and loaded onto 
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polyacrylamide SDS gels before separating by gel electrophoresis and transferring onto 
nitrocellulose membranes. CRTC2, cleaved PARP, cleaved caspase-3, β-actin, and b-tubulin 
proteins were detected by immunoblot analysis with rabbit polyclonal anti-CRTC2, anti-PARP, 
anti-caspase-3, anti-β-actin, and mouse monoclonal anti-b-tubulin antibodies (Supplementary 
Table 4). Protein bands were visualized by chemiluminescence or IRDye detection at 680 or 
800 nm using an autoradiograph film developer or the Odyssey Fc imaging system (LI-COR).   
 
RNA extraction and RT-PCR assays 
Total RNA for quantitative RT-PCR assays were extracted using Trizol reagent (Invitrogen). 
Assays were performed with Kapa SYBR Fast qPCR master mix (Roche) and mRNA 
expression levels of Crtc2 and Prdm1 were quantified with standard curves and results were 
normalized to the expression of Rps18. RT-PCR primer sequences are provided in 
Supplementary Table 4. RNA for sequencing were extracted using the RNeasy Mini Kit 
(Qiagen) and RNase-free DNase (Qiagen). All samples showed an A260/280 ratio > 1.99. Prior 
to library preparation, quality control of the RNA was performed using the Advanced Analytical 
Technologies Fragment Analyzer (Advanced Analytical Technologies, now Agilent 
Technologies) and analyzed using PROSize 2.0.0.51 software. RNA Quality Numbers were 
computed per sample between 8.7 and 10, indicating intact total RNA per sample prior to library 
preparation. 
 
RNA-seq library preparation  
Strand-specific ribosomal RNA depleted RNA-seq libraries were prepared from 1 µg of total 
RNA using the KAPA Stranded RNA-seq Kit with Ribo-Erase (Roche). Samples were prepared 
in at least triplicate for analysis. Briefly, rRNA was depleted from total RNA samples, the 
remaining RNA was heat fragmented, and strand-specific cDNA was synthesized using a first 
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strand random priming and second strand dUTP incorporation approach. Fragments were then 
A-tailed, adapters were ligated, and libraries were amplified using high-fidelity PCR. All libraries 
were prepared in technical duplicates per sample and resulting raw sequencing reads merged 
for downstream alignment and analysis. Libraries were paired-end sequenced at 2x150 bp on 
an Illumina NovaSeq 6000. 
 
RNA-seq data processing 
Raw sequencing runs were filtered for low quality reads and adapter contamination using 
FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc), SeqTK 
(https://github.com/lh3/seqtk), and Cutadapt54. Filtered reads were quantified and quasi-mapped 
to the Mus musculus Gencode M17 (GRCm38.p6) reference transcriptome using the alignment-
free transcript level quantifier Salmon v.0.9.155, 56, 57. The resulting estimated transcript counts 
were summarized into normalized gene level transcripts per million (TPM) and estimated count 
matrices using R (v. 3.4.0) Bioconductor (v. 3.5) package tximport (v. 1.4)58. 
The resulting sample gene count matrix was normalized and analyzed for differential 
gene expression using R (v. 3.4.0) Bioconductor (v. 3.5) package DESeq2 v1.16.059, 60. 
Significance testing was performed using the Wald test, testing for the significance of deviance 
in a full design “Batch + GenotypeStage”, modeling the genotype effect at each division and 
unstimulated time point while accounting for batch variance between matched stimulation 
replicates. Resulting P values were adjusted for multiple testing using the Benjamini-Hochberg 
procedure61. Differentially expressed genes (DEGs) were filtered using an adjusted false 
discovery rate (FDR) P value < 0.05 and an absolute log2(Fold Change) > 0.5 in either the 
stimulated or unstimulated paired conditions.  
Volcano plots were made with ggplot2 as described above, using the DESeq2 output 
adjusted P values and log2-fold changes per TG/WT comparison at each timepoint. Division 
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course kinetic plots were made using ggplot2 with DESeq2 size factor normalized counts using 
function plotCounts(). Gene expression heat maps were prepared using pheatmap() with row Z-
scores calculated as the variance stabilized transform (VST) subtracted by the row mean. PCA 
was plotted using VST values with function plotPCA() with parameter “ntop = 100000”.  
Pathway-level signature gene set enrichment analysis was performed using R 
Bioconductor package GSVA v1.26.0 function gsva() with parameters “method = gsva, rnaseq = 
FALSE, abs.ranking = FALSE, min.sz = 5, max.sz = 500” using a log2(TPM + 1) transformed 
gene expression matrix62. GSVA pathway enrichment scores per sample were extracted and 
assessed for significance using R Bioconductor package limma v3.34.9, as described above 
except with a Benjamini-Hochberg adjusted P value threshold = 0.01. Differentiation signature 
gene sets was obtained for 24 hr CD40L plus IL-4 activated B cells22, 63, GC B cells22, 64, ASCs22, 
64, BLIMP1 activated and repressed targets65, and IRF4 activated-B cell and plasma cell 
targets50.  
Alternative splicing analysis was performed using rMATS v4.0.266. Alternative splicing 
events were selected using an inclusion level difference greater than 0.1 with an FDR < 0.05 for 
any event comparison between Naive, Early, Late, and PC stages. RNA binding motif analysis 
was performed using rMAPS67 using JCEC counts and standard web server settings. Gene 
ontology (GO) term overrepresentation analysis was performed using the combined ASE lists at 
any event comparison, with R packages and parameters as previous described 68. 
Lists of transcript/gene-level expression values and differentiation signature GSVA 
results are included in supplemental excel file Table S1. Lists of alternative splicing events and 
associated GO terms are provided in supplemental excel file Table S2.   
 
Transgene insertion analysis 
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Identification of the transgene insertion site following founder selection was performed using 
BBMap (v.June 11, 2018) (BBtools - sourceforge.net/projects/bbmap/). Following WGS of the 
TG and WT litter-matched mates, sequences were first aligned to the transgene sequence 
cassette using parameters “bbmap.sh in1=jh_wt[tg]_fixedmate_1.fastq.gz 
in2=jh_wt[tg]_fixedmate_2.fastq.gz outm=eitherMapped_jh_wt[tg]_fixedmate.fq 
ref=insertionsequence.fasta”. The resulting aligned sequences were then remapped to the Mus 
musculus mm10 reference genome (NCBI38/mm10, December 2011) to identify sites spanning 
transgene and native genome sequence, using parameters “bbmap.sh 
in=eitherMapped_jh_wt[tg]_fixedmate.fq ref=mm10.fasta 
out=genomeMapped_jh_wt[tg]_fixedmate.sam bs=bs.sh”. The resulting bam files were 
converted into bigWig format and visualized using IGV v2.3.8169.  
 
Metabolomics 
Metabolite extraction and processing of day 5 in vitro stimulated TG and WT B cells were 
performed as previously described53. Data analysis, including principal components analysis 
and clustering, was performed using the statistical language R v3.4.4 and Bioconductor v3.6.0 
packages. Metabolite abundance was normalized per µg of protein content per metabolite 
extraction, and metabolites not detected were set to zero. Metabolite normalized amounts were 
scaled and centered into Z-scores for relative comparison using R base function scale() with 
parameters “scale = TRUE, center = TRUE”. Volcano plots were prepared using R package 
ggplot2 v. 2.2.1; adjusted P values were calculated using R base functions t.test() and p.adjust() 
with parameter “method = ‘BH’” using corrected isotopomer distribution (MID) values. 
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Statistical analyses 
All metabolomics and transcriptomics statistical analyses are described in the above methods. 
Values represent mean ± S.D. or S.E.M. Data were analyzed with Prism 8 (GraphPad) (Figures 
1, 2, 3, 5 and Supplementary Figs. 1, 2, 3) or R (Figure 4 and Supplementary Fig. 1). 
Parametric data were analyzed using two-tailed, unpaired Student’s t-tests, or 2-way ANOVA 
with Bonferroni correction for multiple comparisons. Transcriptomic volcano and kinetic time 
course expression plots were analyzed using DESeq2 Wald tests with Benjamini-Hochberg 
FDR correction for multiple comparisons. For all data sets, P ≤ 0.05 was considered significant. 
*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. 
 
Data and code availability  
All raw RNA-Seq and WGS reads, transcript abundance values, and processed gene count 
matrices are in submission to the NCBI Gene Expression Omnibus (GEO). Accession numbers 
will be provided upon request prior to publication. All RNA-seq, metabolomics, and WGS 
datasets have been provided as supplemental material in this study (Supplementary Tables 1, 
2, and 3). All custom code used for analyses are available on Atlassian BitBucket at 
https://bitbucket.org/ahsanfasih/crtc2bcell/src. All other relevant data are available from the 
corresponding author on request.  
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Figure 1 CRTC2 expression in B cells is repressed during PC differentiation. (a) Immunoblot of 
a representative time-course analysis of phosphorylated and unphosphorylated CRTC2 protein 
expression in naïve splenic B cells stimulated with CD40L and IL-4 over 5 days. Actin was used 
as a loading control. Numbers indicate CRTC2 band intensities normalized to actin and were 
quantified by ImageJ analysis (n = 3 WT and 3 TG). (b) Time-course analysis of Crtc2 mRNA 
expression from naïve splenic B cells stimulated with CD40L and IL-4 by quantitative RT-PCR 
(n = 3 WT and 3 TG). (c) Representative flow cytometry plot at day 5 of CD40L and IL-4 
stimulation showing PC differentiation (boxed region). (d) Quantification of Prdm1 expression at 
day 5 of CD40L and IL-4 induced differentiation by quantitative RT-PCR analysis (n = 5 WT and 
5 TG). Data represent mean ± s.d. (b,c). P values determined by two-tailed, unpaired Student’s 
t-test (b), ****P £ 0.0001.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
51  
Figure 2  
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Figure 2 B cell development is unaffected in Crtc2-AA F1 TG mice. (a) Total Crtc2 mRNA 
expression (endogenous and transgene) from mouse cells isolated from the spleen, thymus, 
and bone marrow by quantitative RT-PCR analysis (n = 3 WT and 3 TG). (b) Representative 
flow cytometry plots of B cell populations in the bone marrow of WT and TG mice (top) and 
quantification of absolute numbers of total, pro-B, pre-B, immature, and mature B cells in the 
bone marrow (bottom). (c) Representative flow cytometry plots of B cell populations in the 
spleen of WT and TG mice (left) and quantification of absolute numbers of total, FO, and MZ B 
cells in the spleen (right). (d) Representative flow cytometry plots of T cells in the thymus of WT 
and TG mice (left) and quantification of absolute numbers of subpopulations in the thymus 
(right). (e) Representative flow cytometry plots of T cells in the spleen of WT and TG mice (left) 
and quantification of absolute numbers of T cell subpopulations in the spleen (right). Each 
symbol (b,c,d,e) represents an individual mouse (n = 7 WT and 8 TG). Data represent mean ± 
s.d. (a,b,c,d,e). P values determined by two-tailed, unpaired Student’s t-test (a), *P £ 0.05. 
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Figure 3 Impaired humoral immune response in TG mice linked to increased PC death. (a) 
Representative flow cytometry plots of plasmablasts (PBs) and plasma cells (PCs) in the spleen 
of unimmunized naïve mice (left) and quantification of PB and PC numbers (right) (n= 8 WT and 
5 TG). (b) Quantification of serum immunoglobulin (Ig) titers from unimmunized WT and TG 
mice (n = 6 WT and 5 TG). (c) Quantification of TNP-specific IgM serum titers from WT and TG 
mice 7 days post-immunization with TNP-Ficoll (n = 6 WT and 6 TG). (d) Quantification of NP-
specific IgM and IgG1 serum titers from WT and TG mice 14 days post-immunization (n = 6 WT 
and 5 TG) and NP-specific IgG1 serum titers from WT and TG mice 35 days post-immunization 
with NP-CGG (n= 3 WT and 3 TG). (e) Representative flow cytometry plots of PCs in the spleen 
of mice infected with Armstrong strain LCMV 8 days post-infection (dpi) (n = 4 WT and 4 TG). (f) 
Quantification of total IgG serum titers from LCMV infected mice 8 dpi. (g) Quantification of 
LCMV-specific IgG serum titers from LCMV infected mice 8 dpi. (h-k) Naïve splenic mouse B 
cells from WT and TG mice were labeled with CFSE and then stimulated with CD40L, IL-4, and 
IL-5. Cells were collected and analyzed at days 0, 3, 4, and 5 of stimulation (n = 5 WT and 4 
TG). (h) Representative flow cytometry plots of WT and TG PC differentiation. Boxed areas 
indicate the percentage of CD138+ PCs. (i) Representative flow cytometry plots showing number 
of cell divisions by TG and WT B cells at day 5 of stimulation by CFSE dye dilution assay. (j) 
Live cells (DAPI-) were gated into early divisions, late divisions, and PC subpopulations and the 
number of cells for each quantified by flow cytometry. (k) Representative immunoblot of cleaved 
PARP and cleaved caspase-3 in WT and TG B cells. Numbers beneath lanes indicate the 
expression of the cleaved forms of PARP and caspase-3 normalized to b-tubulin and as 
arbitrary fluorescence units. Data represent mean ± s.e.m. (a), ± s.d. (b,c,d,f,g,j). P values were 
determined by two-tailed, unpaired Student’s t-test (a,b,c,d,f,g,j), *P £ 0.05, **P £ 0.01, ***P £ 
0.001, ****P £ 0.0001. 
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Figure 4 CRTC2 regulates mRNA expression and alternative splicing in mature B cells. (a) 
Principal component analysis of bulk transcriptomes derived from CD138 and CFSE dye-dilution 
FACS sorted populations described in Supplementary Fig. 1f. Points represent replicates of n 
= 3 independent experiments for WT and TG pairs. PC1 and PC2 scores are plotted on the x- 
and y-axes, respectively. (b) List of differentially expressed genes (DEGs) between WT and TG 
cells at each stage of PC fate specification derived from bulk transcriptomics. Numbers 
represent the number of up-regulated and down-regulated DEGs in each subpopulation. (c) 
Volcano plot of WT and TG cell fold change differences during the PC stage of differentiation. 
Green dots indicate genes up-regulated in the TG population during the PC stage of 
differentiation, whereas red dots indicate down-regulated genes. The adjusted P value cutoff 
represents values < 0.05 calculated using the Wald test following DESeq2 normalization. (d) 
Stage-course expression plots for transcripts of canonical B cell differentiation, PC formation, 
and PC survival markers Bcl6, Irf4, Xbp1, Prdm1, Mcl1, and Cd28. Data represent log2 
transformed DESeq2 normalized counts. (e) Gene set variation analysis (GSVA) results for 
Blimp1 target, Irf4 target, unfolded protein response (UPR) signature, and canonical early 
activation/GC/ASC formation signatures in WT and TG cell populations at each assessed stage 
of differentiation. Data represent n = 3 independent experiments. (f) KEGG overrepresentation 
analysis (ORA) plots indicating pathways enriched in WT versus TG cell differentially expressed 
genes at the PC stage. (g) mRNA alternative splicing events (detected by rMATS 4.0.2) at each 
stage of PC differentiation. Events are split into skipped exon (SE), mutually exclusive exon 
(MXE), alternative 5’ (A5SS) or 3’ (A3SS) splice sites, and retained intron (RI) events. Events 
are detected at an inclusion level difference of 0.10 and an FDR < 0.05 at all stages of 
differentiation between WT and TG cells. (h) Venn diagram displaying the intersection of all 
DEGs from (b) and all mRNA alternative splicing events (ASEs) from (g). (i) Table with selected 
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gene-ontology (GO) and Reactome terms containing genes with significantly affected SE events 
in TG PCs. Adjusted P values were determined by Wald test (d), ****P £ 0.0001 
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Figure 5 Crtc2 repression increases oxidative metabolism. (a) Gene set variation analysis 
(GSVA) results for metabolic signature genes derived from the KEGG database. Results 
represent metabolic gene sets passing a Benjamini Hochberg adjusted P value threshold < 
0.01. Data represent the mean of n = 3 independent experiments. (b) Representative 
extracellular flux analysis of WT and TG PCs. Oxygen consumption rate (OCR) before and after 
treatment with indicated pharmacological inhibitors. Each point represents the mean ± s.d. of n 
= 4 independent experiments. (c) Quantification of basal oxygen consumption rate. (d) 
Quantification of maximal oxygen consumption rate. (e) Quantification of spare respiratory 
capacity. (f) Quantification of basal extracellular acidification rate (ECAR) from extracellular flux 
assay in (b). (g) Volcano plot of steady state metabolite abundances from WT and TG cells at 
day 5 of stimulation with CD40L and IL-4. Plotted are P values for WT and TG cell amounts of 
specific metabolites. Data represent n = 3 independent experiments. P values were determined 
by two-tailed, unpaired Student’s t-test (d,e), *P £  0.05. 
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Figure 6 Crtc2 expression levels trend with ASC longevity. (a) Abundance of Crtc2 transcripts, 
measured in transcripts per million (TPM) in sorted PC subsets from the spleen and bone 
marrow. RNA-seq data from Lam et al., 2018, was re-analyzed to determine transcript 
abundance. The half-life of sorted PC subsets increases from left to right as previously 
determined by Lam et al., 2018. Data represents the mean ± s.d. of n = 3 independent 
experiments. (b) Model in which the level of CRTC2 activity in differentiated ASCs contributes to 
PC longevity. Details are provided in the text.  
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Supplementary Figure 1 Transgenic founder lines, transgene expression, and transgene 
integration analysis. (a) Schematic of the Crtc2-AA transgenic construct used to generate TG 
mouse founder lines. (b) Crtc2-AA transgene expression in bone marrow cells of each TG 
founder line by quantitative RT-PCR analysis (n= 3 for each founder line). (c) Quantification of 
absolute cell numbers from bone marrow B cell subpopulations in TG founder lines F2 and F3 
compared to WT controls (n = 6 WT and 3 each F2, F3 TG). (d) Paired-end whole genome 
sequencing (WGS) of the F1 TG founder mouse to identify transgene integration site(s). 
Genome browser tracks depict mapping of reads to the mouse genome with integration sites 
determined by accumulation of reads that partially align to both the genome and the transgene 
insertion cassette. Data are plotted relative to WT WGS results analyzed in the same pipeline. 
(e) Representative flow cytometry plot of naïve splenic B cells stimulated with CD40L, IL-4, and 
IL-5 used for cell sorting and RNA-seq. At day 5 of stimulation, cells were sorted into early 
division, late division, and PC subpopulations as indicated by boxed areas based on CFSE dye 
dilution assay and CD138 staining. (f) Crtc2 mRNA expression from sorted cell populations as 
outlined in (e). Expression represented as normalized counts for 3 independent RNA-seq 
experiments of WT and TG pairs. Data represent mean ± s.d. (b,c,f). P values were determined 
by two-tailed, unpaired Student’s t-test (b,c), adjusted P values were determined by Wald test 
(f), *P £ 0.05, **P £ 0.01, ***P £  0.001, ****P £ 0.0001.  
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Supplementary Figure 2
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Supplementary Figure 2 ELISPOT images documenting reduction in ASC numbers with PC 
maturation. (a) Quantification of TNP-specific IgM ASCs from the spleen 7 and 14 days post- 
immunization with TNP-Ficoll by ELISPOT (n = 3 WT and 3 TG for each 7 and 14 day 
experiment). (b) Representative images of ELISPOT wells in triplicate revealing IgM secreting 
ASCs at 7 days (left) and at 14 days (right) post TNP-Ficoll immunizations in WT and TG 
splenic cells. (c) Quantification of NP-specific IgM and IgG1 ASCs from the spleen 14 days 
post-immunization with NP-CGG plus alum by ELISPOT (n = 4 WT and 4 TG). (d) 
Representative images of ELISPOT wells in triplicate revealing IgM and IgG1 secreting ASCs at 
14 days post NP-CGG immunizations in alum for WT and TG splenic cells. (e) Quantification of 
NP-specific IgM and IgG1 ASCs from the bone marrow 14 days post-immunization with NP-
CGG plus alum by ELISPOT (n = 4 WT and 4 TG). (f) Representative images of ELISPOT wells 
in triplicate revealing IgM and IgG1 secreting ASCs 14 days post NP-CGG immunizations in 
alum for WT and TG bone marrow cells. Data represent mean ± s.d. (a,c,e). P values were 
determined by two-tailed, unpaired Student’s t-test (a,c,e), *P £ 0.05, **P £ 0.01. 
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Supplementary Figure 3 
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Supplementary Figure 3 Unaffected B cell activation, proliferation, GC formation, and CSR in 
TG B cells. (a,b,c,e) Naïve splenic mouse B cells from WT and TG mice were stimulated with 
CD40L and IL-4. Data represents n = 5 WT and 4 TG (a) Representative flow cytometry plots 
depicting activation marker expression at day 3 of stimulation (top) and quantification of 
activation marker expression by mean fluorescence intensity (MFI) (bottom). (b) Representative 
flow cytometry plots depicting cell division measured using CFSE dye dilution assay at day 3 of 
stimulation. (c) Representative flow cytometry plots depicting differentiation of GC-like B cells at 
day 3 of stimulation (left) and quantification of the percentage of GC-like B cells (right). (d) 
Representative flow cytometry plots depicting differentiation of GC B cells (left) and 
quantification of the percentage and absolute number of GC B cells in the spleen of mice 12 
days post SRBC immunization (n = 6 WT and 5 TG). (e) Representative flow cytometry plots 
depicting class switch recombination (CSR) to the IgG1 isotype at day 3 of stimulation (left) and 
quantification of the percentage of CSR (right). Data represent mean ± s.d. (a,c,d,e). 
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Supplementary Figure 4 Representative gating strategy for flow cytometry analysis. (a) 
Representative gating strategy for analyzing the B cell subpopulations in the bone marrow. (b) 
Representative gating strategy for analyzing the B cell subpopulations in the spleen. (c) 
Representative gating strategy for analyzing the T cell subpopulations in the thymus. (d) 
Representative gating strategy for analyzing the T cell subpopulations in the spleen. (e) 
Representative gating strategy for analyzing the in vitro differentiation of naïve splenic B cells 
into PCs with either CD40L and IL-4 or CD40L, IL-4, and IL-5 stimulations.  
 
Supplementary Table 1 List of transcript and gene-level expression values, GO term 
overrepresentation results, and signature differentiation pathway scores from RNA-seq datasets 
for WT and Crtc2-AA TG B cells during the differentiation stage-course.  
 
Supplementary Table 2 List of mRNA alternative splicing events, differential expression 
overlaps, and GO term overrepresentation analysis of significantly spliced genes. 
 
Supplementary Table 3 List of relative amounts and statistical testing for LC-MS metabolomics 
steady-state abundances between WT and Crtc2-AA TG B cells at day 5 of differentiation. 
 
Supplementary Table 4 List of reagents, antibodies, and oligonucleotides used in this study. 
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Conclusions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
71 
Newly generated ASCs are mostly short-lived, as the frequency of antigen-
specific ASCs drop exponentially during the primary antibody response1. However, the 
question of what regulates the survival and longevity of these cells has not been well 
characterized. Further, the size and capacity of survival niches in the bone marrow and 
other niches in the periphery, appear to be limited, as repeated booster immunizations 
have been shown to release mature PCs that secrete antibodies to alternate antigens 
into the blood stream2. Due to size limitations in these niches, it appears necessary for  
mechanisms to exist which limit the survival of PCs with lower antigen affinity while 
selecting for PCs with higher affinities3. Transcriptional profiling studies of LLPCs and 
SLPCs however, have failed to identify unique transcriptional signatures which could aid 
in elucidating such mechanisms.  
In our study, we generated a TG mouse model to study the in vivo role of CRTC2 
in B cell development, differentiation, and the humoral immune response. In doing so, 
we generated mice with two interesting phenotypes. The first mouse, which we did not 
study beyond initial characterization, exhibits B cell developmental defects in the bone 
marrow which result in spleens that are smaller in size compared to WT controls. The 
second mouse, the subject of this dissertation, exhibits normal B cell development and 
differentiation, but exhibits a defect in PC survival. We further showed that during 
differentiation, Crtc2 expression remained stable in early and late dividing B cell 
populations, but was repressed in the PC population. Remarkably, whereas WT B cells 
repress endogenous Crtc2 expression, TG B cells over-expressed the constitutively 
active and nucleus-localized mutant of Crtc2 (Crtc2-AA) predominantly in the PC 
population. Further characterization of TG B cells revealed no defects in B cell 
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activation, proliferation, or other B cell fates such as CSR, and GC formation. We thus 
generated a mouse model that we can use to study the effects of CRTC2 dysregulation 
in PCs without the confounding factors that upstream defects in B cell responses and B 
cell fates may introduce. 
The most interesting and impactful outcome of our study is that CRTC2 levels 
upon ASC differentiation may dictate the longevity of the ASC pool through its 
regulation of PC metabolism. From our previous and current data, CRTC2 can be 
inactivated and presumably be repressed at the mRNA level by BCR engagement4, 5. If 
proven that the strength of BCR signaling affects the level of Crtc2 repression, we can 
begin to validate our model showing that antigen affinity and Crtc2 expression dictates 
the longevity of PCs. This model attempts to address the question of how newly 
generated PCs in the bone marrow with varying degrees of antigen affinity are selected. 
In our model, PCs with the lowest Crtc2 levels would be longer-lived because of 
increased oxidative metabolism. With increased survival, these PCs may have more 
time to access survival niches and acquire extrinsic survival signals, at which point the 
long-term survival of these cells may then become CRTC2-independent.  
We tested this hypothesis by reanalyzing the RNA sequencing data by Lam et al. 
where they sorted and sequenced mouse splenic and bone marrow PC subsets based 
on B220 expression and 2NBDG import6. In our reanalysis, we confirmed a trend 
existed between PC subsets with longer half-lives and decreased Crtc2 transcript 
levels. Differential gene expression analysis found no statistical significance between 
the sorted PC subsets. However, analysis of the makeup of each sorted PC subset 
revealed a high degree of contamination with other PC subsets, indicating that the 
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sorting purity was low. Perhaps because of this fact, Lam et al. also performed single 
cell RNA-seq of these sorted populations but Crtc2 transcripts dropped out and were 
not counted6. Although not definitive, the data suggests further efforts should be 
pursued in 1) determining that BCR signal strength can directly affect Crtc2 levels and 
2) potentially performing our own single cell RNA sequencing of sorted PC subsets to 
analyze Crtc2 transcript levels. Unfortunately, due to the low abundance and limitations 
in identifying PCs of varying half-lives and then sorting them, further studies may prove 
difficult without new methodologies7. 
Metabolic regulation of B cells is clearly important for B cell development, 
differentiation, and function. PBs differentiated by the TI antigen LPS, upregulate 
oxidative metabolism genes in a BLIMP1 dependent manner in order to support the 
production of antibodies8. In addition, PCs have been shown to increase import of 
glucose and amino acids and upregulate glycolysis and oxidative metabolism9. Further, 
a recent study of IRF4 which is critical for PC survival, found IRF4 regulated genes 
associated with metabolic pathways and maintained mitochondrial homeostasis10. As 
the CRTC family of co-activators have been associated with energy metabolism, 
mitochondria, and longevity, it perhaps was expected CRTC2 would affect 
metabolism11, 12, 13. Although we were unable to establish a direct mechanism for the 
deficiency in oxidative metabolism in TG PCs, GSVA of metabolic programs suggested 
a potential defect in metabolic reprogramming as TG PCs were shown to be 
metabolically more similar to WT and TG late dividing cells than WT PCs . Since we did 
not perform metabolic flux analysis with heavy isotope labeled glucose or glutamine, we 
were unable to determine how carbons were used in TG and WT PCs and therefore 
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cannot confirm a defect in metabolic reprogramming. However, gene expression and 
steady state metabolite profiling data does suggest a defect in the glycolytic pathway in 
TG PCs which would lead to a reduction in pyruvate synthesis. Additionally, it appears 
that TG PCs compensate for this defect by utilizing glutamine to fuel the TCA cycle. 
Both steady state metabolite profiling coupled with metabolic flux analysis will give us a 
clearer picture of how CRTC2 is affecting PC metabolism. Furthermore, determining the 
levels of TCA metabolites, such as a-ketoglutarate and succinate, which regulate 
epigenetic modifiers may provide insights into whether there is also an impairment in 
epigenetic regulation of gene programs in TG compared to WT PCs14, 15. 
Additionally, Lam et al. established that the mitochondrial morphology of SLPCs 
and LLPCs were similar16. Much of the mitochondria’s function can be determined by its 
size and morphology. Fused mitochondria are associated with increased oxidative 
metabolism, whereas fragmented mitochondria show inhibition of oxidative 
metabolism17. High-resolution confocal microscopy of TG and WT PCs revealed that 
there were no intrinsic differences in mitochondrial morphology, size, and abundance 
(data not shown). However, although TG PCs appear to compensate for the lack of 
pyruvate synthesis with glutamine anaplerosis, TG PCs still exhibit defects in oxidative 
metabolism. One explanation for this is that TG PCs may have defects in the individual 
electron transport chain (ETC) protein activity or supercomplex formation which would 
result in oxidative metabolism defects. TG PCs do in fact exhibit aberrant splicing of 
Cep89, Ndufaf7, and Sirt3 which all have known roles in regulating ETC complex 
activity and formation18, 19, 20. It will be important to perform biochemical studies to 
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analyze ETC complex activity and to determine the extent of CRTC2 mediated 
metabolic defects in TG PCs.  
We also observed that CD28, which is expressed in PCs and is critical for LLPC 
survival21, is repressed 2.6-fold in TG PCs. CD28 activation establishes SRC and 
increases glycolysis and OXPHOS in memory T cells22. A previous study claimed that 
the pro-survival effect mediated by CD28 is through the translational upregulation of 
ATG5, increased autophagy activity, and elevated oxidative metabolism23. Interestingly, 
the study by Lam et al. also revealed an increase in autophagy staining in their sorted 
PC subsets. However, the increase in autophagy staining in PC subsets with longer 
half-lives was stated to be modest and subtle with unclear significance7. In our study, 
the transcriptional levels of Atg5 were unchanged between TG and WT B cells, but we 
did not assess ATG5 protein levels, nor did we analyze autophagy. It will be interesting 
to see whether TG B cells are deficient in autophagy to determine another potential 
mechanism that could explain the reduced levels of oxidative metabolism and reduced 
survival in TG B cells. Additionally, CD28 has also been shown to regulate at the 
translational level, the expression of the anti-apoptotic factor BCL-XL24. The lack of 
transcriptional differences between LLPCs and SLPCs suggests the potential for 
alternative means of regulation and requires analyses beyond mRNA expression 
quantification. Performing Western blot analysis on a selection of important factors that 
regulate differentiation and survival may be warranted to confirm that critical factors are 
unchanged at the translational levels in TG and WT PCs. Further, performing 
proteomics studies on TG and WT PCs to determine differential protein expression may 
uncover relevant factors and pathways that could regulate survival and longevity. 
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Surprisingly, we found CRTC2 inactivation and repression was required for the 
fidelity of mRNA alternative splicing programs. Although a previous study had shown 
over-expression of CRTC family members affect exon usage of in vitro splicing reporter 
assays, our study is the first to show in a physiologically relevant system that a CRTC 
family member can regulate alternative splicing. Since we did not perform CRTC2 ChIP-
sequencing analysis of the PC population, it is unknown whether CRTC2 directly binds 
to the genes with alternative splicing events. Differential gene expression analysis did 
reveal numerous spliceosome related genes that were differentially expressed in TG 
PCs. However, whether these small magnitude changes in gene expression could 
account for the observed changes in alternative splicing events in TG compared to WT 
cells is unknown and perhaps unlikely. Interestingly, motif analysis of all genes that 
exhibited alternative splicing events, revealed an enrichment for the RNA binding motif 
protein 47 (RBM47).  
RBM47 has been shown to regulate alternative splicing, stability, and abundance 
of several mRNAs. High-throughput sequencing and cross-linking immunoprecipitation 
(HITS-CLIP) analysis, which generates genome-wide protein-RNA interaction maps 
revealed that RBM47 bound predominantly to intronic and 3’UTRs of mRNAs25. In lung 
cancer cell lines, RBM47 bound genes were shown to regulate oxidative metabolism 
related genes. When RBM47 was knocked down in these lung cancer cell lines, 
oxidative metabolism was increased26. This suggests that RBM47, which was over-
expressed by more than 4-fold in TG PCs may directly affect the splicing of many of the 
genes that exhibit aberrant splicing. Further work establishing RBM47 binding sites and 
direct target genes in TG and WT PCs by performing HITS-CLIP analysis should reveal 
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an important and previously unrecognized role for RBM47 in regulating PC metabolism 
and survival. 
The study covered in this dissertation highlights a new and exciting role for 
CRTC2 in B cell biology. We show that by regulating both gene expression and mRNA 
alternative splicing programs in PCs, CRTC2 repression is required to regulate oxidative 
metabolism and survival of PCs. Over the course of this study, we were surprised to 
realize that TG PCs exhibited characteristics that mirrored the phenotype associated 
with SLPCs16. Therefore, we proposed a model where CRTC2 levels in differentiated 
ASCs could potentially regulate the ability of PCs to survive and establish long-term 
residency in survival niches. We were able to establish a trend between reduced Crtc2 
transcript levels and increased PC longevity, but further work will be required to validate 
this model. By beginning to delineate the molecular basis for PC metabolism and 
survival, we may be able in the future to modulate metabolic pathways in PCs for 
therapeutic means, either to enhance the efficacy of immunizations or to inhibit PCs that 
secrete pathogenic autoantibodies.  
 
 
 
 
 
 
 
 
 
 
 
 
78 
References 
 
1. Sze, D.M., Toellner, K.M., Garcia de Vinuesa, C., Taylor, D.R. & MacLennan, I.C. 
Intrinsic constraint on plasmablast growth and extrinsic limits of plasma cell 
survival. J Exp Med 192, 813-821 (2000). 
 
2. Odendahl, M. et al. Generation of migratory antigen-specific plasma blasts and 
mobilization of resident plasma cells in a secondary immune response. Blood 
105, 1614-1621 (2005). 
 
3. Xiang, Z. et al. FcgammaRIIb controls bone marrow plasma cell persistence and 
apoptosis. Nat Immunol 8, 419-429 (2007). 
 
4. Kuraishy, A.I. et al. TORC2 regulates germinal center repression of the TCL1 
oncoprotein to promote B cell development and inhibit transformation. Proc Natl 
Acad Sci U S A 104, 10175-10180 (2007). 
 
5. Sherman, M.H. et al. AID-induced genotoxic stress promotes B cell differentiation 
in the germinal center via ATM and LKB1 signaling. Mol Cell 39, 873-885 (2010). 
 
6. Lam, W.Y. et al. Metabolic and Transcriptional Modules Independently Diversify 
Plasma Cell Lifespan and Function. Cell Rep 24, 2479-2492 e2476 (2018). 
 
7. Lam, W.Y. & Bhattacharya, D. Metabolic Links between Plasma Cell Survival, 
Secretion, and Stress. Trends Immunol 39, 19-27 (2018). 
 
8. Price, M.J., Patterson, D.G., Scharer, C.D. & Boss, J.M. Progressive 
Upregulation of Oxidative Metabolism Facilitates Plasmablast Differentiation to a 
T-Independent Antigen. Cell Rep 23, 3152-3159 (2018). 
 
9. Akkaya, M. & Pierce, S.K. From zero to sixty and back to zero again: the 
metabolic life of B cells. Curr Opin Immunol 57, 1-7 (2019). 
 
10. Low, M.S.Y. et al. IRF4 Activity Is Required in Established Plasma Cells to 
Regulate Gene Transcription and Mitochondrial Homeostasis. Cell Rep 29, 2634-
2645 e2635 (2019). 
 
11. Escoubas, C.C., Silva-Garcia, C.G. & Mair, W.B. Deregulation of CRTCs in Aging 
and Age-Related Disease Risk. Trends Genet 33, 303-321 (2017). 
 
12. Altarejos, J.Y. & Montminy, M. CREB and the CRTC co-activators: sensors for 
hormonal and metabolic signals. Nat Rev Mol Cell Biol 12, 141-151 (2011). 
 
13. Burkewitz, K. et al. Neuronal CRTC-1 governs systemic mitochondrial 
metabolism and lifespan via a catecholamine signal. Cell 160, 842-855 (2015). 
 
 
 
79 
14. Lu, C. & Thompson, C.B. Metabolic regulation of epigenetics. Cell Metab 16, 9-
17 (2012). 
 
15. Zan, H. & Casali, P. Epigenetics of Peripheral B-Cell Differentiation and the 
Antibody Response. Front Immunol 6, 631 (2015). 
 
16. Lam, W.Y. et al. Mitochondrial Pyruvate Import Promotes Long-Term Survival of 
Antibody-Secreting Plasma Cells. Immunity 45, 60-73 (2016). 
 
17. Galloway, C.A. & Yoon, Y. Mitochondrial dynamics in diabetic cardiomyopathy. 
Antioxid Redox Signal 22, 1545-1562 (2015). 
 
18. van Bon, B.W. et al. CEP89 is required for mitochondrial metabolism and 
neuronal function in man and fly. Hum Mol Genet 22, 3138-3151 (2013). 
 
19. Zurita Rendon, O., Silva Neiva, L., Sasarman, F. & Shoubridge, E.A. The 
arginine methyltransferase NDUFAF7 is essential for complex I assembly and 
early vertebrate embryogenesis. Hum Mol Genet 23, 5159-5170 (2014). 
 
20. Ahn, B.H. et al. A role for the mitochondrial deacetylase Sirt3 in regulating energy 
homeostasis. Proc Natl Acad Sci U S A 105, 14447-14452 (2008). 
 
21. Rozanski, C.H. et al. Sustained antibody responses depend on CD28 function in 
bone marrow-resident plasma cells. J Exp Med 208, 1435-1446 (2011). 
 
22. Klein Geltink, R.I. et al. Mitochondrial Priming by CD28. Cell 171, 385-397 e311 
(2017). 
 
23. Peng, P., Chavel, C., Utley, A., Carlson, L., and Lee, KP. CD28 Regulates 
Autophagy to Enhance Plasma Cells Survival.  Journal of Immunology; 2019; 
2019. 
 
24. Wu, L.X. et al. CD28 regulates the translation of Bcl-xL via the 
phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway. J 
Immunol 174, 180-194 (2005). 
 
25. Vanharanta, S. et al. Loss of the multifunctional RNA-binding protein RBM47 as 
a source of selectable metastatic traits in breast cancer. Elife 3 (2014). 
 
26. Sakurai, T. et al. RNA-binding motif protein 47 inhibits Nrf2 activity to suppress 
tumor growth in lung adenocarcinoma. Oncogene 35, 5000-5009 (2016). 
 
 
 
 
 
 
80 
APPENDIX I: 
 
 
AID-induced genotoxic stress promotes B cell differentiation in the 
 
germinal center via ATM and LKB1 signaling 
 
  
 
 
81 
 
 
 
 
Molecular Cell
Article
AID-Induced Genotoxic Stress Promotes
B Cell Differentiation in the Germinal Center
via ATM and LKB1 Signaling
Mara H. Sherman,1,10 Ali I. Kuraishy,2,10 Chetan Deshpande,8 Jason S. Hong,3 Nicholas A. Cacalano,4 Richard A. Gatti,3
John P. Manis,9 Michael A. Damore,8 Matteo Pellegrini,1,5 ,6 ,7 and Michael A. Teitell1,3 ,6 ,7,*
1Molecular Biology Institute
2Department of Human Genetics
3Department of Pathology and Laboratory Medicine, David Geffen School of Medicine
4Department of Radiation Oncology
5Department of Molecular, Cell, and Developmental Biology
6California NanoSystems Institute and Jonsson Comprehensive Cancer Center
7Broad Center of Regenerative Medicine and Stem Cell Research
University of California, Los Angeles, Los Angeles, CA 90095, USA
8Department of Molecular Sciences, Amgen Inc., Thousand Oaks, CA 91320, USA
9Department of Pathology, Harvard Medical School, Boston, MA 02115, USA
10These authors contributed equally to this work
*Correspondence: mteitell@mednet.ucla.edu
DOI 10.1016/j.molcel.2010.08.019
SUMMARY
During an immune response, B cells undergo rapid
proliferation and activation-induced cytidine deami-
nase (AID)-dependent remodeling of immunoglob-
ulin (IG) genes within germinal centers (GCs) to
generate memory B and plasma cells. Unfortunately,
the genotoxic stress associated with the GC reaction
also promotes most B cell malignancies. Here, we
report that exogenous and intrinsic AID-induced
DNA strand breaks activate ATM, which signals
through an LKB1 intermediate to inactivate CRTC2, a
transcriptional coactivator of CREB. Using genome-
wide location analysis, we determined that CRTC2
inactivation unexpectedly represses a genetic
program that controls GC B cell proliferation, self-
renewal, and differentiation while opposing lympho-
magenesis. Inhibition of this pathway results in
increased GC B cell proliferation, reduced antibody
secretion, and impaired terminal differentiation.
Multiple distinct pathway disruptions were also iden-
tified in human GC B cell lymphoma patient samples.
Combined, our data show that CRTC2 inactivation,
via physiologic DNA damage response signaling,
promotes B cell differentiation in response to geno-
toxic stress.
INTRODUCTION
DNA double-strand breaks (DSBs) are generated during the
assembly and diversification of antigen receptor genes in devel-
oping lymphocytes. During early B cell maturation in the bone
marrow, the recombinase activating gene (RAG) endonuclease
generates complete antigen receptor genes by the process of
V(D)J recombination (Fugmann et al., 2000; Tonegawa, 1983).
The generation of a diverse repertoire of high-affinity antibodies
(Abs) requires further modifications of the immunoglobulin (IG)
genes (Rajewsky, 1996; Revy et al., 2000) in secondary lymphoid
follicles within compartments known as germinal centers (GCs).
GCs are sites within lymphoid tissues where mature B cells
rapidly proliferate, modify IG gene sequences, and differentiate
in response to a stimulating antigen. A key feature of IG remod-
eling is class switch recombination (CSR), a process that
modifies the effector function of an Ab by replacing one constant
region of the IG gene with another. CSR requires activation-
induced cytidine deaminase (AID)-generated DSB intermediates
(Chaudhuri et al., 2003; Muramatsu et al., 2000) and subsequent
repair of distal severed ends. This genomic remodeling is
critical for a robust Ab response, but genotoxic stress associated
with the GC reaction also promotes most human lymphomas
(Ku¨ppers and Dalla-Favera, 2001).
In order to preserve genomic integrity, mammalian cells
undergoing genotoxic stress usually respond by activating
a complex DNA damage response (DDR). This response, which
is required to prevent tumor formation, includes inhibition of
cellular proliferation and/or induction of apoptosis (Khanna and
Jackson, 2001). In GC B cells, the DDR is coordinated by the
ATM serine/threonine kinase, which senses DSBs in concert
with the MRN (MRE11-RAD50-NBS1) complex (Kastan and
Bartek, 2004). This response is critical for humoral immunity
and evasion of tumorigenesis because defects in CSR and
increased chromosomal lesions occur in activated mature B
cells from mice lacking ATM (Lumsden et al., 2004; Reina-San-
Martin et al., 2004) or its target proteins 53BP1 (Manis et al.,
2004; Ward et al., 2004), H2AX (Franco et al., 2006), NBS1
(Kracker et al., 2005; Reina-San-Martin et al., 2005), and
MDC1 (Lou et al., 2006).
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During theGC reaction, B cells express the BCL6 oncoprotein,
which functions as a transcriptional repressor of the PRDM1
gene encoding BLIMP-1 (Shaffer et al., 2000), the master regu-
lator of plasma cell differentiation (Turner et al., 1994). Impor-
tantly, BCL6 also suppresses key components of the DDR in
the GC by repressing the expression of ATR (Ranuncolo et al.,
2007), TP53 (Phan and Dalla-Favera, 2004), and CDKN1A (P21)
(Phan et al., 2005). This suppression may enable GC B cells
to proliferate rapidly without triggering cellular senescence or
apoptosis programs, although the resulting modified DDR
increases the susceptibility of GC B cells to malignant transfor-
mation. Accordingly, BCL6 downregulation is required for
post-GC B cell differentiation and evasion of tumorigenesis
(Cattoretti et al., 2005).
ATM promotes and BCL6 represses the DDR, representing
antagonistic forces in the life of a GC B cell. To terminate the
GC reaction, rapidly proliferating B cells must tip this balance
toward exiting the cell cycle to allow for terminal differentiation,
although amechanism initiating this shift has not been identified.
Previously, we showed that B cell antigen receptor (BCR)
engagement led to cytoplasmic sequestration and inactivation
of the CREB transcriptional coactivator CRTC2 (TORC2),
causing downregulation of the TCL1 oncogene in GC B cells
(Kuraishy et al., 2007). Studies of glucose metabolism regulation
have shown that CRTC2 inactivation results from phosphoryla-
tion at S-171 (Screaton et al., 2004) and/or S-275 (Jansson
et al., 2008) by members of the AMPK family, promoting a phys-
ical association betweenCRTC2 and the cytoplasmic chaperone
14-3-3. However, the physiologic event(s) that inactivate CRTC2
in GC B cells are unknown. Because GC B cells experience both
DNA damage and CRTC2 inactivation-dependent TCL1 repres-
sion, we hypothesized that CRTC2 is inhibited by the DDR
and that CRTC2 controls an extended gene program beyond
TCL1. Testing of this hypothesis led to the discovery of a DDR
pathway in GC B cells, with exogenous or intrinsic AID-induced
DSBs activating ATM signaling to LKB1, a master kinase for
AMPK family member proteins (Lizcano et al., 2004), which
then resulted in the inactivation of CRTC2. Suggesting a role
as a key homeostatic regulator, changes in gene expression re-
sulting from CRTC2 inactivation were essential for cessation of
the GC reaction, plasma cell differentiation, and suppression of
tumorigenesis.
RESULTS
DNA Double-Strand Breaks Inactivate CRTC2
To determine whether DNA damage inactivates CRTC2, we
induced DSBs in the Ramos human GC B cell line by using eto-
poside (Eto) or g-irradiation (IR), which are known to generate
g-H2AX foci (Phan et al., 2007). Subcellular fractionation showed
that DSBs caused a shift in CRTC2 localization from the nucleus
to the cytoplasm (Figure 1A). This change in CRTC2 location was
accompanied by an increased association between CRTC2 and
the cytoplasmic chaperone 14-3-3 (Figure 1B) (Jansson et al.,
2008; Screaton et al., 2004). Chromatin immunoprecipitation
(ChIP) showed a >4-fold reduction in the association between
CRTC2 and the CRTC2-responsive TCL1 promoter with DSBs
(Figure 1C). DSBs also repressed expression of the TCL1
promoter (Figure 1D and Figures S1A–S1C, available online).
Combined, these data show that DSBs inactivate CRTC2,
leading to repression of CRTC2-dependent gene expression.
DSB-Induced CRTC2 Inactivation Requires Activation
of ATM and LKB1
We next tried to identify a link between DSBs and CRTC2 inacti-
vation. Since the DNA damage-sensing kinase ATM is required
for CSR (Lumsden et al., 2004; Reina-San-Martin et al., 2004),
we evaluated ATM for a role in CRTC2 inactivation. Induced
DSBs in Ramos cells activated ATM (Figure S2A). ATM loss of
function, using two different shRNA sequences targeting ATM,
pharmacological inhibition with the ATM inhibitor Kudos, and
the use of B cell lines from ATM-deficient ataxia-telangiectasia
(A-T) patients showed a requirement for ATM in DSB-induced
CRTC2 inactivation (Figures 2A–2D and Figures S2B–S2D).
ATM phosphorylates multiple substrates during the DDR
(Matsuoka et al., 2007), potentially including T366 of the tumor
suppressor LKB1 (Fernandes et al., 2005; Sapkota et al.,
2002). In turn, LKB1 phosphorylates and inactivates CRTC2
through AMPK family members (Fu and Screaton, 2008; Katoh
et al., 2006; Shaw et al., 2005), suggesting a pathway from
DSBs to CRTC2 inactivation. DSBs caused ATM-dependent
phosphorylation of LKB1 T366 (Figures S2E and S2F). Similarly,
DSBs induced LKB1 phosphorylation in primary B cells
(Figure S2G). Metformin is an antidiabetic drug that promotes
LKB1-dependent activation of AMPK (Shackelford and Shaw,
2009; Shaw et al., 2005). Ramos cells exposed to metformin
showed reduced nuclear localization of CRTC2 and TCL1
repression (Figures S2H–S2J). shRNA knockdown of LKB1
with two different sequences lessened CRTC2 inactivation in
response to DSBs in Nalm-6 pre-B cells (Figures S2K and S2L)
and Ramos cells (Figures 2E–2G, Figures S2M and S2N). These
data demonstrate that DSBs inactivate CRTC2 via ATM and
LKB1 signaling, providing a gene regulation mechanism during
the DDR.
CRTC2 Inactivation Occurs during CSR in GC B Cells
To determine the role of CRTC2 in GC B cells, we evaluated
changes in CRTC2 activity and direct target gene expression
over the course of a GC reaction. For this, we modified an
in vitro B cell differentiation system starting with naive human
tonsil B cells (Figure 3A) (Arpin et al., 1995; Fluckiger et al.,
1998). Rapid B cell expansion and correct modulation of estab-
lished GC B and plasma cell markers (BCL6, MYC, OCA-B, and
BLIMP-1) occurred over 7 days, as expected for a GC-like reac-
tion (Figures 3B–3D) (Allman et al., 1996; Greiner et al., 2000;
Shaffer et al., 2008). Though undetectable on day 3, soluble and
membrane-bound IgG (32% of cells) was detected by day 7
(Figure 3E and Figure S3A), preceded byg-H2AX focus formation
by day 5 (Figure S3B) (Petersen et al., 2001). These results indi-
cate thatCSR followedbyplasmacell differentiationwas induced
during a GC-like reaction between days 3 and 7 of culture.
CRTC2 activity was evaluated during the interval in which CSR
occurred. Nuclear CRTC2 decreased between days 3 and 7
(Figure 3F) with a coinciding decrease in the association
between CRTC2 and the TCL1 promoter and decreased TCL1
expression, as observed in vivo (Figures 3G and 3H) (Said
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et al., 2001; Teitell et al., 1999). Importantly, similar CRTC2
modulation was observed during GC B cell development
in vivo (Figure S3C) (Klein et al., 2003; Said et al., 2001), with
!70% of plasma cells containing entirely cytoplasmic CRTC2
and !30% negative for CRTC2 protein expression. Combined,
these results strongly suggest that CRTC2 becomes phosphor-
ylated and sequestered in the cytoplasm and inactivated during
CSR in vivo, resulting in reduced expression of CRTC2-depen-
dent target genes, such as TCL1 (Figure S3D).
AID-Dependent ATM to LKB1 Signaling in GC B Cells
Inactivates CRTC2
The requirement for ATM and LKB1 as upstream regulators of
CRTC2 inactivation was assessed in the modeled GC-like
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Figure 1. DNA Double-Strand Breaks Inactivate CRTC2
(A) Top: immunoblot showing CRTC2 protein expression in the nucleus (N) and cytoplasm (C) of Ramos B cells exposed to DMSO (control), Eto (20 mM, 1 hr), or IR
(5Gy). Upper bands in the cytoplasm lanes indicate phosphorylatedCRTC2. b-TUBULIN (cytoplasm) and HDAC1 (nucleus) are loading controls. Bottom: nuclear/
cytoplasmic ratios for CRTC2 are plotted from densitometry.
(B) Top: immunoprecipitation of CRTC2 or rabbit IgG from lysates of Ramos cells exposed to DMSO or Eto (20 mM, 1 hr). Bottom: untreated cells were compared
to cells exposed to IR (5 Gy). Immunoblots for lysates (Input) and CRTC2 or 14-3-3 immunoprecipitates (IP) are shown.
(C) ChIP for CRTC2 or rabbit IgG using chromatin from Ramos cells after DMSO, Eto (20 mM, 1 hr), or IR (5Gy). Immunoprecipitates were analyzed by qPCR for the
TCL1 promoter. Valueswere normalized to theACTB promoter and shown as arbitrary units (a.u.). Values are expressed as themean ± SEM for three independent
experiments.
(D) Top: qPCR for TCL1 in Ramos cells after DMSO or Eto (20 mM, 6 hr). Bottom: untreated cells were compared to cells exposed to the indicated doses of IR.
Values were normalized to 36B4. Values are expressed as the mean ± SEM for three independent experiments.
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reaction. An increase in phospho-ATM S1981 was detected by
day 7 (Figure 4A), coinciding with DSB generation during CSR.
ATM knockdown (Figure 4B) resulted in increased CRTC2
nuclear localization during B cell differentiation compared to
control cells (Figure 4C). Similar results were obtained for
LKB1 (Figures 4D–4F). These data strongly suggest that GC-
like B cells responding to physiologic DSBs activate ATM to
LKB1 signaling to inactivate CRTC2. This pathway is engaged
during the period of CSR, further suggesting a link to Ab produc-
tion and B cell maturation.
To directly determine whether CSR drives CRTC2 inactivation,
we compared the subcellular localization of CRTC2 in B cells
from wild-type (WT) and AID knockout mice. AID-deficient B
cells cannot produce DSBs at IG loci and therefore CSR does
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Figure 2. DSB-Induced CRTC2 Inactivation Requires Activation of ATM and LKB1
(A) Immunoblot showing ATM knockdown in Ramos cells 4 days after transduction. HSP70 is a loading control.
(B) Top: immunoblot showing CRTC2 protein expression in the nucleus (N) and cytoplasm (C) of Ramos cells transduced with control (Scr) shRNA or shATM after
exposure to DMSO or Eto (20 mM, 1 hr). b-TUBULIN (cytoplasm) and HDAC1 (nucleus) are loading controls. Bottom: nuclear/cytoplasmic ratios for CRTC2 are
plotted from densitometry.
(C) qPCR for TCL1 in shATM or control (Scr) Ramos cells after DMSO or Eto (20 mM, 6 hr) exposure. Values were normalized to 36B4. Values are expressed as the
mean ± SEM for three independent experiments.
(D) qPCR for TCL1 in WT or ATM-deficient lymphoblastoid cells exposed to DMSO or Eto (20 mM, 6 hr). Values were normalized to 36B4. Values are expressed as
the mean ± SEM for three independent experiments.
(E) Immunoblot showing LKB1 knockdown in Ramos cells 4 days after transduction. b-ACTIN is a loading control.
(F) Top: immunoblot showing CRTC2 protein expression in the nucleus (N) and cytoplasm (C) of Ramos cells transduced with control (Scr) shRNA or shLKB1 after
exposure to DMSO or Eto (20 mM, 1 hr). b-TUBULIN (cytoplasm) and HDAC1 (nucleus) are loading controls. Bottom: nuclear/cytoplasmic ratios for CRTC2 are
plotted from densitometry.
(G) qPCR for TCL1 in shLKB1 or control (Scr) Ramos cells after DMSOor Eto (20 mM, 6 hr) exposure. Values were normalized to 36B4. Values are expressed as the
mean ± SEM for three independent experiments.
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not occur (Muramatsu et al., 2000). aCD40 and IL-4 inducedCSR
in!43% of WT but not in AID knockout B cells (Figure S4). Most
importantly, CRTC2 was retained in the nucleus of AID knockout
B cells compared to its nuclear depletion in WT B cells
(Figure 4G). This result strongly supports the requirement for
physiologic DSBs induced by AID during CSR for ATM- and
LKB1-dependent CRTC2 inactivation.
CRTC2 Regulates Genes that Control B Cell
Development
The effect of CRTC2 inactivation on global gene expression in
GC B cells was evaluated. ChIP-on-chip for CRTC2 target genes
in Ramos cells was performed with two Abs that recognize
distinct CRTC2 epitopes (Figure S5A). The genomic DNA bound
to CRTC2 and total input DNA were distinctly labeled and
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Figure 3. CRTC2 Inactivation Occurs during CSR in GC B Cells
(A) Schematic of primary human B cell differentiation system.
(B) Phase-contrast image of expanding human B cell clusters 24 hr after stimulation (at a magnification of 53).
(C) qPCR forOCA-B,BCL6, andPRDM1 in humanB cells at 0, 3, or 7 days of differentiation. Values are normalized to 36B4 and are expressed as themean ± SEM
for three independent experiments.
(D) Immunoblot for BCL6, BLIMP-1, OCA-B, and MYC in primary human B cells after 0, 3, or 7 days of differentiation. b-ACTIN is a loading control.
(E) ELISA for total IgG in human B cell culture media harvested after 0, 3, or 7 days of differentiation. n.d. = none detected. Values are expressed as the mean ±
SEM for three independent experiments.
(F) Top: immunoblot showing CRTC2 protein expression in the nucleus (N) and cytoplasm (C) of primary human B cells on days 3 or 7 of differentiation.
b-TUBULIN (cytoplasm) and HDAC1 (nucleus) are loading controls. Bottom: nuclear/cytoplasmic ratios for CRTC2 are plotted from densitometry.
(G) ChIP for CRTC2 using chromatin from human B cells after 3 or 7 days of differentiation. Immunoprecipitates were analyzed by qPCR for the TCL1 promoter.
Values are normalized to an intergenic region and shown as a.u. Values are expressed as the mean ± SEM for three independent experiments.
(H) qPCR for TCL1 in human B cells after 3 or 7 days of differentiation. Values are normalized to 36B4. Values are expressed as the mean ± SEM for three inde-
pendent experiments.
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Figure 4. AID-Dependent ATM to LKB1 Signaling in GC B Cells Inactivates CRTC2
(A) Immunoblot of pATM (S1981) and ATM in human B cells after 3 or 7 days of differentiation. b-TUBULIN is a loading control.
(B) Immunoblot showing ATM knockdown in human B cells 3 days after shATM transduction. HSP70 is a loading control. Densitometric values are indicated
below each band.
(C) Top: immunoblot showing CRTC2 protein expression in the nucleus (N) and cytoplasm (C) of primary human B cells, transduced with control (Scr) or shATM-
expressing lentiviruses, on days 3 or 7 of differentiation. b-TUBULIN (cytoplasm) and HDAC1 (nucleus) are loading controls. Bottom: nuclear/cytoplasmic ratios
for CRTC2 are plotted from densitometry.
(D) Immunoprecipitation of phosphorylated ATM/ATR substrates (pSQ/TQ) or a rabbit IgG control from lysates of human B cells after 3 or 7 days of differentiation.
Lysates (Total LKB1) or immunoprecipitates (LKB1) are analyzed by immunoblot for LKB1.
(E) Immunoblot showing LKB1 knockdown in human B cells 3 days after shLKB1 transduction. b-ACTIN is a loading control. Densitometric values are indicated
below each band.
(F) Top: immunoblot showing CRTC2 protein expression in the nucleus (N) and cytoplasm (C) of primary human B cells, transduced with control (Scr) or shLKB1-
expressing lentiviruses, on days 3 or 7 of differentiation. b-TUBULIN (cytoplasm) and HDAC1 (nucleus) are loading controls. Bottom: nuclear/cytoplasmic ratios
for CRTC2 are plotted from densitometry.
Molecular Cell
AID-Induced DSBs Drive B Cell Differentiation
878 Molecular Cell 39, 873–885, September 24, 2010 ª2010 Elsevier Inc.
 
 
87 
 
 
 
cohybridized to Agilent 244K human promoter microarrays that
contained 60-mer oligonucleotide probes covering the region
from !5.5 kb to +2.5 kb relative to the transcriptional start sites
for"17,000 annotated human genes. The vast majority of bound
sequences were located within 1 kb of transcriptional start sites
(Figure 5A), consistent with a previous global analysis of CREB
promoter occupancy (Zhang et al., 2005). This approach
revealed that CRTC2 occupied the promoters of 5993 genes
(Figures S5B and S5C). Motif analysis among the bound
sequences identified conventional CRE half-sites as the two
most highly enriched of all possible 6-mers (p = 10!22.5;
Figure S5D), as anticipated for a coactivator of CREB. Gene
expression profiling was also performed with Ramos cells
treated with Eto or anti-IgM Ab, which was also shown to inacti-
vate CRTC2 (Kuraishy et al., 2007). This screen identified 136
putative CRTC2-regulated genes (Figure 5B, Table S1) impli-
cated in cellular growth and proliferation, the cell cycle, and
cancer (Figure 5C).
To validate these findings, we selected ten candidate CRTC2
target genes that have functional relevance for GC B cell devel-
opment and/or lymphomagenesis. Gene-specific ChIP demon-
strated enrichment for promoter regions of these ten candidate
(G) Top: immunoblot showing CRTC2 protein expression in the nucleus (N) and cytoplasm (C) of spleen B cells from WT or AID knockout (AID!/!) mice on days
0 and 4 of differentiation. b-TUBULIN (cytoplasm) and HDAC1 (nucleus) are loading controls. Bottom: nuclear/cytoplasmic ratios for CRTC2 are plotted from
densitometry.
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Figure 5. CRTC2Regulates aGene Program
that Controls B Cell Development
(A) Plotted z scores for CRTC2 binding to human
promoter regions relative to the predicted tran-
scriptional start sites (TSS).
(B) Venn diagram displaying putative CRTC2 direct
target genes as defined by downregulation with
exposure to a-IgM Ab and Eto and CRTC2 binding
to the promoter region.
(C) Gene ontology (GO) analysis of candidate
CRTC2 target genes. p values are based on
a hypergeometric distribution.
(D) ChIP for CRTC2 or rabbit IgG in Ramos cells.
Immunoprecipitates were analyzed by qPCR for
the promoters of CRTC2 target genes. Values are
normalized to intergenic regions and shown as
a.u. Values are expressed as the mean ± SEM for
three independent experiments.
(E) qPCR for CRTC2 target genes in Ramos
cells after DMSO or Eto (20 mM, 6 hr) exposure.
Values are normalized to 36B4 and are expressed
as the mean ± SEM for three independent experi-
ments.
(F) qPCR for CRTC2 target genes in Ramos cells
with or without a-IgM (10 mg/ml, 6 hr) exposure.
Values are normalized to 36B4. Values are
expressed as the mean ± SEM for three indepen-
dent experiments.
(G) Immunoblot for CRTC2 protein expression
in Ramos cells 48 hr after infection with the indi-
cated lentivirus. HSP70 is a loading control.
(H) qPCR for CRTC2 target genes in Ramos cells
transduced with the indicated lentivirus. DMSO
or Eto (20 mM, 6 hr) exposures were initiated
48 hr after infection. Values are normalized to
36B4 and are expressed as the mean ± SEM for
three independent experiments.
(I) ChIP for CRTC2 using chromatin from human
B cells after 3 or 7 days of differentiation. Immuno-
precipitates were analyzed by qPCR for the
promoters of CRTC2 target genes. Values are
normalized to intergenic regions, are shown as
a.u., and are expressed as the mean ± SEM for
three independent experiments.
(J) qPCR for CRTC2 target genes in human B cells
after 3 or 7 days of differentiation. Values are normalized to 36B4 and are expressed as the mean ± SEM for three independent experiments.
(K) qPCR for CRTC2 target genes in human B cells transduced with the indicated lentivirus after 3 or 7 days of differentiation. Values are normalized to 36B4 and
are expressed as the mean ± SEM for three independent experiments.
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CRTC2 target genes with a CRTC2 Ab compared to an isotype
control (Figure 5D). Gene expression changes were measured
with Eto or anti-IgM treatment, with quantitative polymerase
chain reaction (qPCR) validating the expression array results
(Figures 5E and 5F). To determine a causal relationship between
CRTC2 inactivation and downregulation of candidate CRTC2
target genes, we used a lentiviral expression system to trans-
duce Ramos cells with WT or mutant CRTC2 in which serines
171 and 275 were mutated to alanines (CRTC2-AA; Figure 5G
and Figure S5E). CRTC2-AA should remain in the nucleus
because both serines require phosphorylation by AMPK to
exclude CRTC2 from the nucleus (Jansson et al., 2008; Screaton
et al., 2004). CRTC2-WT overexpression or continued activation
by CRTC2-AA caused a derepression of the ten target genes
with DSBs or with anti-IgM exposure (Figure 5H and Figure S5F),
indicating that expression of these genes is dependent upon
CRTC2 activity. Similar results were obtained from primary
human B cells (Figures 5I–5K). Supporting the connection
between genotoxic stress and CRTC2 target gene regulation,
pretreatment of Ramos cells with the ATM inhibitor Kudos
caused a significant depression of CRTC2 target genes with
DSBs (Figure S5I). In addition, a significant derepression of
CRTC2 target genes occurred when DSBs were induced in
immortalized B cells from A-T patients, which lack functional
ATM, compared to WT controls (Figure S5G). A-T cells also
exhibited a striking retention of CRTC2 in the nucleus after Eto
exposure compared to WT controls (Figure S5H).
CRTC2 Inactivation Is Required for Plasma Cell
Differentiation
To determine the effect of signaling that inactivates CRTC2 on B
cell development, we stimulated naive tonsil B cells efficiently
transduced with CRTC2-WT or CRTC2-AA to generate a GC-
like reaction. Proliferating GCB cells, or centroblasts, are among
the fastest proliferating cells in the body (Klein and Dalla-Favera,
2008), and plasma cell differentiation is characterized in part by
repression of pro-proliferative gene expression (Shaffer et al.,
2002). Hyperactive or overexpressed CRTC2 caused a marked
increase in proliferation (Figure 6A), a decrease in soluble IgG
production (Figure 6B), impaired induction of the plasma cell
master regulator BLIMP-1 (Figure 6C), and sustained expression
of the GC B cell master regulator BCL6 (Figure 6D) on day 7 of
culture. Similar results were obtained when ATM or LKB1
expression was decreased by shRNAs (Figures 6E–6H). Interest-
ingly, transduced CRTC2 did not impair CSR, as equivalent
levels of productive IGG transcripts were generated in CRTC2-
overexpressing and control cells (Figures S6A and S6B). These
data strongly suggest that the DDR pathway leading to CRTC2
inactivation is required for efficient termination of theGC reaction
and Ab secretion.
CRTC2 Inactivation Is Disrupted in GC-Derived B Cell
Lymphomas
Since TCL1 is often overexpressed in GC B cell lymphomas
(Klein et al., 2001; Narducci et al., 2000; Said et al., 2001), we
assessed this signaling pathway in human lymphoma samples.
qPCR analysis revealed a 10-fold or greater loss of ATM expres-
sion in 6/17 (35%), or LKB1 expression in 7/17 (41%), clinical
samples (Figures 7A and 7B).CRTC2 expression was not altered
in these tumors (data not shown), so the CRTC2 coding
sequence was evaluated for alterations. A C/Tmissensemuta-
tion was identified in 10/17 tumor samples, compared with 0/14
normal tonsil samples (p < 0.0005, one-sided Fisher’s exact test)
(Figure 7C and Figure S7). This change results in a L/F amino
acid substitution in the AMPK recognition sequence of the
CRTC2 protein (Screaton et al., 2004). Although this alteration
is conservative, it prevented inactivation of CRTC2 in Ramos B
cells subjected to DSBs (Figures 7D and 7E), perhaps by disrupt-
ing AMPK-CRTC2 or CRTC2-14-3-3 interactions. Consistent
with this result, TCL1 expression was maintained in 11 of 13 B
cell lymphomas that harbored disruptions in the ATM/
LKB1/AMPK/CRTC2 signaling pathway (Figure 7F). These
results provide evidence for aberrant CRTC2 activity in human
lymphomas from multiple, distinct defects in a DDR pathway.
DISCUSSION
Here, we describe a mechanism in which exogenous and phys-
iologic DNA damage in GC B cells leads to CRTC2 inactivation,
which is required for IG secretion and plasma cell differentiation.
Although a prior study showed a BCR signaling requirement for
Ab affinity-driven plasma cell development (Phan et al., 2006),
the cues that cause GC B cells to differentiate into plasma cells
are unknown. Previously, we showed that CRTC2 is also inacti-
vated by BCR engagement (Kuraishy et al., 2007), suggesting
that CRTC2 inactivation is a response to both genotoxic stress
and BCR signaling, which terminates the GC reaction. More
broadly, these results also implicate LKB1 as a central kinase
with the potential to integrate metabolic and now AID-initiated
genotoxic stress signaling in a pathway that can terminate with
CRTC2 inactivation to drive terminal cell differentiation.
Our results, along with aspects of two recent studies, provide
an important direction for the DDR by coupling genotoxic stress
to non-DNA-repair-related physiologic or pathologic cellular
maturation. One recent study in pre-B cells demonstrated that
RAG-induced DSBs during V(D)J recombination activated tran-
scription by NF-kB, leading to the expression of mature lympho-
cyte-specific genes (Bredemeyer et al., 2008). However, this
study required genetically sustained RAG-induced DSBs to
detect mature lymphocyte gene expression, leaving open the
question of physiologic relevance. A second recent study
showed that genotoxic stress opposed self-renewal in melano-
cyte stem cells (MSCs) and caused the MSCs to aberrantly
differentiate into ectopically pigmented melanocytes, resulting
in irreversible hair graying (Inomata et al., 2009). This form of
abnormal differentiation resulted from pathologic DNA damage
accumulation from the environment, which led to lineage degen-
eration and aging by an unknown mechanism. In contrast, our
study shows a mechanism linking physiologic, AID-induced
DSBs to ATM and LKB1 signaling in order to inactivate
CRTC2, with CRTC2 inactivation required for the differentiation
of plasma cells. This regulatory function exceeds the established
response to DSBs that maintains genomic integrity, and it
provides evidence that the DDR influences normal cell develop-
ment and physiology. A potential ontologic reason for coupling
genotoxic stress with differentiation is that the forced elimination
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of damaged cells from stem or precursor cell pools, such as the
GC, may be an intrinsic mechanism to preserve the integrity of
preterminal cell types and prevent tumorigenesis.
A consistent theme that re-emerges from studies of hemato-
poietic development is that a block in differentiation seems to
promote a malignancy that reflects the stage in development
at which the block occurs. Here, we show that disruption of
the signaling pathway leading to CRTC2 inactivation and plasma
cell differentiation occurs in GC-derived lymphomas. Because
ATM is required for CRTC2 inactivation, defects in this pathway
may contribute in part to the IG deficiencies (Nowak-Wegrzyn
et al., 2004; Staples et al., 2008) and increased susceptibility to
lymphoma (Taylor et al., 1996) observed in patients with A-T.
In addition to mutations, aberrant ATM repression in multiple
B cell lymphoma subtypes has also been reported (Basso
et al., 2005). Like ATM, the LKB1 tumor suppressor is inactivated
in a number of human malignancies (Hezel and Bardeesy, 2008;
Shaw, 2008). Furthermore, a small population-based case-
control study showed that diabetics taking metformin, which
activates LKB1 and results in CRTC2 inactivation, had a reduced
risk of cancer (Evans et al., 2005). In mice, a hypomorphic muta-
tion in Lkb1 present on a Pten haploinsufficient background
markedly accelerated the development of marginal-zone B cell
lymphoma (Huang et al., 2008). Interestingly, PTEN deficiency
is similar to aberrantly sustained TCL1 expression for mature B
cells because both alterations hyperactivate AKT signaling
(Teitell, 2005).
In summary, CRTC2 plays a powerful and previously unknown
role in normal GC B cell differentiation, and its inactivation by the
DDR is critical for downregulation of a genetic program that
maintains the GC reaction. These findings place CRTC2 in
a regulatory pathway that controls GC exit and plasma cell
D
B
F
H
E
G
A
C
*p = 0.008
*
0
5
10
15
20
25
30
35
FUGW CRTC2
WT
CRTC2
AA
%
 B
rd
U-
po
sit
ive
 c
e
lls
*
*
*p ≤0.0001
0
1
2
3
4
FUGW CRTC2 WT CRTC2 AA
Se
cr
et
ed
 Ig
G
(ng
/m
l)
**
*
*p = 0.0004; **p = 0.002
0
20
40
60
80
Day 3 Day 7 Day 3 Day 7 Day 3 Day 7
FUGW CRTC2 WT CRTC2 AA
R
el
. e
xp
re
ss
io
n
BCL6
β-ACTIN
FUGW CRTC2 WT CRTC2 AA
0.181.00 0.392.58 1.213.54
0.861.07 31.100.1 1.061.10
Day 3Day 3Day 3 Day 7Day 7Day 7
**
*
*p = 0.001
**p = 0.002
0
10
20
30
40
50
60
70
Scr shATM shLKB1
%
 B
rd
U-
po
sit
ive
 c
e
lls
*
**
*p = 0.007
**p = 0.003
0
1
2
3
4
5
6
7
8
9
Scr shATM shLKB1
Se
cr
et
ed
 Ig
G
(ng
/m
l)
*
*
*p ≤0.0001
0
10
20
30
40
50
60
Day 3 Day 7 Day 3 Day 7 Day 3 Day 7
Scr shATM shLKB1
R
el
. e
xp
re
ss
io
n
Scr shATM shLKB1
BCL6
β-ACTIN
Day 3Day 3Day 3 Day 7Day 7Day 7
0.301.00 0.480.77 1.020.75
0.851.00 0.810.76 0.920.77
Figure 6. CRTC2 Inactivation is Required for
Plasma Cell Differentiation
(A) BrdU incorporation in human B cells, trans-
duced with the indicated lentivirus, on day 7 of
differentiation. BrdU-FITC-positive cells were
detected by flow cytometry. Values are expressed
as the mean ± SEM for three independent
experiments.
(B) ELISA for total secreted IgG in human B cell
culture media harvested after day 7 of differentia-
tion. Cells were transduced with the indicated
lentivirus prior to the initiation of differentiation.
Values are expressed as the mean ± SEM for three
independent experiments.
(C) qPCR for PRDM1 expression in human B cells
transduced with the indicated lentivirus after 3 or
7 days of differentiation. Values are normalized to
36B4 and are expressed as the mean ± SEM for
three independent experiments.
(D) Immunoblot for BCL6 in human B cells trans-
duced with the indicated lentivirus after 3 or
7 days of differentiation. b-ACTIN is a loading
control. Densitometric values are indicated below
each band.
(E) BrdU incorporation in human B cells, trans-
duced with the indicated lentivirus, on day 7 of
differentiation. BrdU-FITC-positive cells were
detected by flow cytometry. Values are expressed
as the mean ± SEM for three independent experi-
ments.
(F) ELISA for total secreted IgG in human B cell
culture media harvested after day 7 of differentia-
tion. Cells were transduced with the indicated
lentivirus prior to the initiation of differentiation.
Values are expressed as the mean ± SEM for three
independent experiments.
(G) qPCR for PRDM1 in human B cells transduced
with the indicated lentivirus after 3 or 7 days of
differentiation. Values are normalized to 36B4
and are expressed as the mean ± SEM for three
independent experiments.
(H) Immunoblot for BCL6 in human B cells, trans-
duced with the indicated lentivirus, after 3 or
7 days of differentiation. b-ACTIN is a loading
control. Densitometric values are indicated below
each band.
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differentiation during terminal B cell development and herald
future studies to interrogate the role of CRTC2 as a potential
oncogenic factor and therapeutic target in B cell lymphoma.
EXPERIMENTAL PROCEDURES
Cell Culture, Tissues, and Reagents
Wild-type, Atm!/!, Lkb1(T366A), and Lkb1!/!MEFs (N. Bardeesy, Massachu-
setts General Hospital) were grown in Dulbecco’s modified Eagle’s medium
(GIBCO, USA) with 20% fetal bovine serum (FBS) plus antibiotics. Nalm-6,
Ramos, PBL, and ATM-deficient lymphoblastoid cells were grown in RPMI
1640 (GIBCO) with 10% FBS plus antibiotics. Fresh-frozen human tissues
and fresh human tonsils were obtained from the University of California, Los
Angeles (UCLA) Tissue Procurement Core Laboratory in accordancewith insti-
tutional guidelines and Institutional Review Board approval. Reagents
included etoposide, mitomycin C, and metformin (Sigma, USA) and the ATM
inhibitor KU55933 (Kudos Pharmaceuticals, UK). a-CD40 (mouse anti-human
IgG) was purified from a culture medium of G28-5 mouse hybridoma cells
(K. Zhang, UCLA).
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Figure 7. CRTC2 Inactivation Is Disrupted in
GC-Derived B Cell Lymphomas
(A) qPCR for ATM in 17 human lymphoma samples
and two tonsils. Values are normalized to 36B4
and are expressed as the mean ± SEM for three
independent experiments. The following abbrevia-
tions are used: Ton., tonsil; DLBCL, diffuse large B
cell lymphoma; BL, Burkitt lymphoma; FL, follicular
lymphoma.
(B) qPCR for LKB1 in 17 human lymphoma sam-
ples and two tonsils. Values are normalized to
36B4 and are expressed as the mean ± SEM for
three independent experiments.
(C) Representative chromatograms showing a
CRTC2 496 C/T alteration in human GC B cell
lymphomas. Arrow indicates nucleotide 496 in
the coding region of CRTC2.
(D) Immunoblot showing expression of CRTC2 and
FLAG in Ramos cells 48 hr after infection with the
indicated lentivirus. b-ACTIN is a loading control.
(E) Top: immunoblot showing exogenous CRTC2
localization in Ramos cells, transduced with
the indicated lentivirus, after DMSO or Eto
(20 mM, 1 hr) exposure. b-TUBULIN (cytoplasm)
and HDAC1 (nucleus) are loading controls.
Bottom: nuclear/cytoplasmic ratios for CRTC2
are plotted from densitometry.
(F) qPCR for TCL1 expression in 13 human B cell
lymphoma samples and in GC B cells at day 3 of
culture. Values are normalized to 36B4 and
compared to TCL1 expression in differentiated
plasma cells at day 7 of culture. Dashes indicate
tumors with undetectable TCL1 expression.
Primary Human B Cell Culture System
Fresh tonsils were used to isolate naive B cells as
described (Said et al., 2001). Tonsils were minced,
and mononuclear cells (MCs) were isolated by Fi-
coll-Paque (GE Healthcare, USA) density centrifu-
gation. MCs were incubated with a-IgD-PE (BD
PharMingen, USA) on ice, washed, incubated
with a-PE beads (Miltenyi Biotech), washed, and
collected using the MidiMACS system (Miltenyi
Biotec, Germany). Lentiviral transduction was per-
formed at this stage, as indicated. Cells were
seeded 5 3 105 cells/ml and cultured in complete RPMI 1640 plus 20 ng/ml
IL-4, 20 ng/ml IL-10 (BD PharMingen), and 2 mg/ml a-CD40 Ab.
ELISA
ELISA was performed with a human IgG ELISA quantification kit (Bethyl Labo-
ratories, USA).
RNA Analysis
Total RNAwas extracted with Trizol (Life Technologies, USA). cDNAwasmade
with the Superscript First-Strand Synthesis System (Invitrogen, USA). qPCR
was performed as described previously (Kuraishy et al., 2007). Expression
was normalized to a 36B4 mRNA control sequence.
Immunoblot, Immunoprecipitation, and Antibodies
Immunoblots were performed as described (Kuraishy et al., 2007). Briefly,
20–50 mg whole-cell extract for each sample was separated by SDS-PAGE
and transferred to a nitrocellulose membrane. Blocked membranes were
incubated with primary Abs in TBS-Tween and 5% milk (or 5% BSA for phos-
phospecific Abs) overnight (Ab sources provided upon request). Immunopre-
cipitations were performed with whole-cell extracts and primary Ab overnight,
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followed by precipitation of immune complexes with Protein G beads (Santa
Cruz Biotechnologies, USA). Subcellular fractionations were performed with
the NE-PER Nuclear and Cytoplasmic Extraction kit (Thermo Scientific, USA)
according to the manufacturer’s protocol.
Chromatin Immunoprecipitation
ChIP assays were performed as described (Kuraishy et al., 2007).
Immunofluorescence Microscopy
Ramos or primary B cells were plated on poly-L-lysine coverslips and used for
immunofluorescence studies as described (Kuraishy et al., 2007).
siRNA Electroporation
LKB1 siRNA (2 mM; Dharmacon) or a scrambled control siRNA (2 mM)was elec-
troporated into Nalm-6 cells with the AmaxaNucleofector I (programC-05) and
Nucleofector kit T (Amaxa, Germany).
Retrovirus and Luciferase Assays
Luciferase assays were performed as described (Kuraishy et al., 2007).
A pBABE-FLAG-LKB1 retroviral construct, expressing FLAG-tagged LKB1,
was generated by standard methods. Viral supernatant from HEK293T cells
was collected 48 and 72 hr after transfection. PBL cells (1 3 105/well)
were incubated with 1ml of virus supplemented with 2 ml polybrene and centri-
fuged at 2500 rpm for 1 hr at 30!C. One day after repeat infection, puromycin
(0.5 mg/ml) was added to the media. FLAG-LKB1 expression was determined
by western blot.
Lentivirus
For shRNA, theH1 promoter and RNAi sequences for LKB1,ATM, or scramble
were subcloned into FUGW at the PacI site upstream of a ubiquitin promoter-
driven EGFP sequence (Lois et al., 2002). For expression vectors, full-length
CRTC2 cDNA was cloned into FUGW downstream of the ubiquitin promoter.
CRTC2 mutants were generated with the Quikchange site-directed mutagen-
esis kit (Stratagene, USA). Virus produced byHEK293T cells was concentrated
by ultracentrifugation, resuspended in RPMI 1640, and used to spin-infect
2 3 106 cells/well in a 24-well plate for 2 hr.
In Vitro Proliferation Assays
In vitro proliferative kinetics were assayed with the BrdU flow kit (BD
PharMingen) according to the manufacturer’s protocol.
ChIP-on-Chip
ChIP was performed with two different Abs against CRTC2 (EMD Biosciences,
USA; Cell Signaling, USA). Biological duplicate experiments were performed
with each Ab. Array details are in the Supplemental Experimental Procedures.
Gene Expression Arrays
RNA was isolated from Ramos cells without treatment or after 6 hr of Eto
(20 mM) or a-IgM (10 mg/ml) exposure using Trizol, followed by clean-up with
the QIAGEN RNeasy kit. Array details are in the Supplemental Experimental
Procedures.
Gene Ontology Analysis
Gene ontology analysis was performed with Ingenuity Pathways Analysis.
Statistical Analyses
Data are presented as the mean ± standard error of the mean (SEM).
A two-tailed t test was used for most comparisons, with p < 0.05 considered
significant.
ACCESSION NUMBERS
All ChIP-on-chip and gene expression microarray data have been deposited
in the Gene Expression Omnibus (GEO) under the submission number
GSE23171.
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Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
doi:10.1016/j.molcel.2010.08.019.
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Ampk regulates IgD expression 
but not energy stress with B cell 
activation
Lynnea R. Waters1,2, Fasih M. Ahsan 2, Johanna ten Hoeve3,4,5, Jason S. Hong2, 
Diane N. H. Kim6, Aspram Minasyan  3,5, Daniel Braas3,4,5, Thomas G. Graeber 3,4,5,7,8,9, 
Thomas A. Zangle  10,11 & Michael A. Teitell1,2,6,7,8,9,12
Ampk is an energy gatekeeper that responds to decreases in ATP by inhibiting energy-consuming 
anabolic processes and promoting energy-generating catabolic processes. Recently, we showed that 
Lkb1, an understudied kinase in B lymphocytes and a major upstream kinase for Ampk, had critical and 
unexpected roles in activating naïve B cells and in germinal center formation. Therefore, we examined 
whether Lkb1 activities during B cell activation depend on Ampk and report surprising Ampk activation 
with in vitro B cell stimulation in the absence of energy stress, coupled to rapid biomass accumulation. 
Despite Ampk activation and a controlling role for Lkb1 in B cell activation, Ampk knockout did not 
significantly affect B cell activation, differentiation, nutrient dynamics, gene expression, or humoral 
immune responses. Instead, Ampk loss specifically repressed the transcriptional expression of IgD and 
its regulator, Zfp318. Results also reveal that early activation of Ampk by phenformin treatment impairs 
germinal center formation but does not significantly alter antibody responses. Combined, the data 
show an unexpectedly specific role for Ampk in the regulation of IgD expression during B cell activation.
B lymphocyte activation is an early step in a humoral immune response, whereby a naïve B cell with a unique 
antigen receptor recognizes its cognate antigen to trigger growth, division, and differentiation. Following acti-
vation, selected B cells can develop into long-lived plasma cells that secrete antigen-specific antibodies to fight 
infections1. During receptor-mediated activation, B cells undergo class switch recombination (CSR), also called 
immunoglobulin isotype switching, to modify the type of B cell antigen receptor (BCR) expressed by the B cell, 
such as IgM or IgG1 isotypes2. Many of the early signaling events linked to engagement of the BCR are well 
studied3. Recently, we reported a role for the tumor suppressor Lkb1 in B cell activation: Lkb1 knockout (KO) 
caused spontaneous B cell activation in vivo without specific added antigenic stimulation, resulting in a robust 
T cell-dependent germinal center (GC) reaction4,5. This result was interesting because Lkb1 signaling had not 
been previously implicated in B cell activation and few models of spontaneous GC formation exist6. We therefore 
sought to determine the mechanism(s) whereby Lkb1 controls B cell activation.
Lkb1 phosphorylates 14 different related kinase family member proteins to control many cellular functions 
including protein synthesis and cell growth, cell polarity, and metabolism7. We elected to examine one of these 14 
major downstream Lkb1 targets, 5′ AMP-activated protein kinase (Ampk). Ampk is an energy sensor that couples 
metabolism with nutrient availability during periods of energetic stress, as might occur during rapid B cell expan-
sion and differentiation8. Ampk does this by sensing increasing levels of ADP or AMP with reducing levels of ATP 
in a cell, which triggers the phosphorylation of well characterized substrate proteins including Tsc2, Acc1/2, and 
Tbc1d1 to inhibit protein synthesis, promote fatty acid oxidation, upregulate glycolysis, and restore overall cell 
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energy balance9. While Lkb1 is the major upstream kinase for Ampk, other upstream kinases also phosphorylate 
Ampk including CamKK2 and Tak110–12. In T cells, CD3 ligation results in rapid Ampk activation in a calcium- 
and CamKK2-dependent manner13, and Ampk activation declines in proliferating normal T cells14; however, the 
Ampk activation pattern in B cells is unknown.
Studies of Lkb1 and Ampk have shown overlapping but also unique functions in hematopoiesis. For exam-
ple, Lkb1 maintains hematopoietic stem cell quiescence by regulating metabolism and the cell cycle using 
Ampk-dependent and -independent mechanisms15–17. In T cells and thymocytes, Lkb1 deletion reduced periph-
eral T cells and decreased T cell proliferation when stimulated in vitro. However, while loss of Ampk in T cells 
also led to metabolic and activation defects, it did not fully recapitulate the loss of Lkb118–20. There is only one 
reported study of Ampk in B cells, which showed that a whole mouse knockout of Ampk left isolated B and T cells 
unable to survive in vitro under oxidative stress when exposed to the ATP synthase inhibitor, oligomycin21. Given 
the unexpected role for Lkb1 loss in B cells in triggering a GC reaction, we sought to determine role(s) for Ampk 
during B cell activation.
Results
Ampk activation during B cell stimulation. Initially, we investigated whether Ampk, a major down-
stream target of Lkb1, was required for B cell activation4,5. Previous studies in T cells showed Ampk activation 
after T cell receptor stimulation13. We examined the phosphorylation of Ampk at T172, a marker residue for 
Ampk activation22 and determined that Ampk activation occurs between 18–24 hours post-stimulation of B cells 
with anti-CD40 antibody plus interleukin (IL)-4 that persists at least through 72 hours (Fig. 1A). Activation of 
Ampk should initiate cellular processes that halt the accumulation of biomass required for cell division9. Instead, 
anti-CD40 plus IL-4 stimulated B cells to divide rapidly between 48–72 hours (Fig. 1B). Ampk activation with 
energy stress has been reported many times and occurs by sensing decreasing amounts of ATP linked to increas-
ing ratios of AMP:ATP and ADP:ATP23. Therefore, we examined a previously published dataset of nucleotide 
metabolite levels at 24 hours post-stimulation. UHPLC-MS metabolomics data of 13C6-glucose nutrient labeling 
during initial B cell activation showed unexpected AMP:ATP and ADP:ATP ratios declining at 24 hours with ATP 
steady-state levels significantly increasing (Fig. 1C)24. Additional measurements of extracellular nutrients shows 
maintenance of high levels of both glucose and glutamine in the culture medium (Fig. 1D), indicating that Ampk 
activation occurs in stimulated B cells during energy replete conditions.
Since Ampk activation typically inhibits protein, lipid, and additional biosynthetic processes, we turned to live 
cell interferometry, a form of quantitative phase microscopy, as a high precision and reproducible approach to 
quantify changes in biomass accumulation during early B cell activation25 (Fig. 1E). We discovered that isolated 
naïve mouse B cells steadily increase cell biomass over the first 48 hours of anti-CD40 plus IL-4 stimulated activa-
tion (Fig. 1F). Interestingly, the specific growth rate calculated as a percentage of biomass change per hour accel-
erates for the first 18 hours and then plateaus (Fig. 1G). This growth rate peak coincides with the timing of Ampk 
activation (Fig. 1A), although despite Ampk activity B cells continue to acquire biomass at the peak (plateau) rate. 
This growth rate profile suggests that Ampk activation may damp further growth rate acceleration, perhaps as a 
rate-limiting step, but does not impede the overall growth of B cells.
Ampk is not required for B cell activation or differentiation. It was a surprise that Ampk was acti-
vated in stimulated naïve mouse B cells because a major role for Ampk in inhibiting lipid and protein synthesis 
seems incompatible with the high growth rate and cell division of activated B cells. Thus, we sought to determine 
whether Ampk was required for B cell activation and differentiation by generating a mouse model with B cell 
specific deletion of Ampk. Because Ampkα1, encoded by Prkaa1, is the only α subunit expressed in trimeric 
Ampk proteins in mature B cells26, deletion of this catalytic subunit abolishes all Ampk activity. We generated 
a B cell specific Ampkα1 KO mouse line by crossing Prkaa1fl/fl mice with CD19-Cre  recombinase driver mice 
to delete Ampk activity in post-pro/pre B cells. To monitor deletion efficiency, we crossed mice with a Rosa26 
lox-STOP-lox YFP reporter allele (Fig. 2A). Deletion efficiency measured by YFP+ B220+ B cells was >80% in 
both WT (Prkaa1+/+ × CD19-Cre) and Ampk KO (Prkaafl/fl × CD19-Cre) mice (Fig. 2B), suggesting that there is 
no B cell survival disadvantage with loss of Ampk, in contrast to a major B cell survival disadvantage with Lkb1 
loss4. Analysis of lysates from naïve and anti-CD40 plus IL-4 stimulated WT and Ampk KO B cells confirmed 
loss of Ampkα1 protein and abolishment of Ampk activity in Ampk KO B cells (Fig. 2C). Use of a pan-Ampk 
alpha (α1 and α2) antibody also allows us to conclude that there was no compensatory expression of the Ampkα2 
subunit upon deletion of Ampkα1.
To determine whether Ampk deletion affects B cell activation, we stimulated isolated WT and Ampk KO B 
cells with anti-CD40 plus IL-4 and assessed activation and differentiation of YFP+ B cells. Surprisingly, despite 
Ampk activation at 24 hours, no changes in the levels of expression of activation markers CD69, CD86 or MHCII 
occur for the Ampk KO B cells compared to WT B cells. At later time points, no changes in GC-like B cell differ-
entiation at day 3 and a minor reduction in CSR to IgG1 occurred in Ampk KO compared to WT B cells. By day 
5, there was a small trending increase in plasmablast differentiation in Ampk KO versus WT B cells (Fig. 2D). 
These data strongly contrast with deletion of Lkb1 in B cells, which causes opposing results including increased 
activation marker expression and GC-like B cell differentiation, an increase in CSR, and a decrease in plasmablast 
differentiation4. Together, the results suggest that Ampk is not required for normal B cell function and is not 
required for Lkb1-dependent B cell phenotypes.
Ampk does not control a humoral immune response in vivo. We next examined whether Ampk 
deletion from B cells affects antibody responses in vivo. A prior study showed that whole mouse KO of Ampk did 
not affect IgG responses to Ars-KLH antigen in vivo21; however, other potential effects on the GC reaction, CSR, 
or antibody specificity were not examined. We inoculated Ampk KO and WT mice with the T cell-dependent 
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Figure 1. Activation of Ampk upon stimulation of B cells is independent of energy stress and does not result in 
lowered biomass accumulation. (A) Representative time course western blot for phosphorylated Ampkα (T172), 
Ampkα, and β-tubulin during anti-CD40 plus IL-4 stimulation of B cells. Image was cropped for clarity, full-length 
blots/gels are presented in Supplementary Fig. 1. (B) Representative flow cytometry of B220+ B cells at 0, 24, 
48 and 72 hours post anti-CD40 plus IL-4 stimulation stained with Cell Trace Violet. (C) Relative fold change in 
previously published UHPLC- MS metabolomics dataset24 for adenine nucleotides from 24 hours post stimulation 
with anti-CD40 plus IL-4 relative to naïve B cells (n = 3). (D) Measurement of extracellular glucose and glutamine 
at 24 hours post stimulation with anti-CD40 plus IL-4 (n = 3). (E) Live cell interferometry (LCI) images of 
anti-CD40 plus IL-4 activated B cells 1, 24, and 48 hours post stimulation showing significant growth, as confirmed 
by (F) a significant increase in average cell mass over time, binned into 3 h increments. (G) Average specific growth 
rate, computed as the instantaneous slope of mass over time for each cell normalized by cell mass, shows a peak at 
24 hours, coincident with Ampk inactivation (n = 5 independent experiments of at least 200 cells). Data represent 
mean ± SD (C,D) or SEM (F,G). P values determined by 2-way ANOVA with Bonferroni correction for multiple 
comparisons (C) or an unpaired two-tailed Student’s t-test (D). **P ≤ 0.01.
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antigen, NP-(28)-CGG, and analyzed B cells on day 14 post-immunization. We observed no differences in GC 
formation or CSR (Fig. 2E), and serum IgG1 levels were similar between WT and Ampk KO mice, with a slight 
but statistically insignificant difference in total IgM (Fig. 2F). Multivalent NP antigen enables detection of highly 
specific antibodies by probing for binding to specific NP molar ratios, with fewer NP molecules revealing higher 
specificity responses. Our data show that both broad spectrum and highly specific IgG1 against NP antigen were 
similar in WT and Ampk KO mice (Fig. 2F). These results show that Ampk is dispensable for a T cell-dependent 
humoral immune response, although Ampk may be critical in other contexts, such as T cell-independent, 
mucosal, or antiviral immune responses.
Figure 2. Ampk deletion does not significantly impair B cell function. (A) Strategy for generating B-cell 
lineage specific knockout of Prkaa1 by crossing CD19-Cre  recombinase (JAX: 006785) mice with Prkaa1fl/fl 
(JAX: 014141) mice and Rosa26 lox-STOP-lox YFP (JAX: 006148) mouse lines, yielding mice where CD19+ B 
cells lack the catalytic Ampkα subunit. (B) Quantification of Cre-recombinase efficiency by measurement of 
percentage of B220+ B cells that have YFP expression by flow cytometry in WT and Ampk KO B cells (n = 3). 
(C) Representative Western blot for P-Ampkα (T172), Ampkα and β-tubulin in WT and Ampk KO mice. 
Two exposures are shown for Ampkα to illustrate some remaining Ampk expression. Image was cropped for 
clarity, full-length blots/gels are presented in Supplementary Fig. 2. (D) Flow cytometry of WT and Ampk KO 
B cells during activation with anti-CD40L plus IL-4, including activation markers (MHCII, CD86, CD69) at 
24 hours, GC differentiation (GC, %B220+ Fas+ GL7+) and CSR (%B220+ IgG1+) at day 3, and plasmablast 
differentiation (%B220lo CD138+) at day 5 (n = 5 for MHCII, CD86, CD69, and PB, n = 6 for GC, and n = 7 
for CSR). (E) Flow cytometry of total splenocytes after immunization. Representative plots and quantification 
of GC differentiation (GC B Cells, B220+ Fas+ GL7+) and CSR (B220+ IgG1+) 14 days post-immunization 
with NP-(28)-CGG (n = 4). (F) Total IgM, total IgG1, NP8 IgG1, NP20 IgG1, and NP8/NP20 IgG1 ratio in 
serum 14 days after immunization of WT and Ampk KO mice with NP-(28)-CGG (n = 4). (G) Representative 
flow cytometry for 2NBDG glucose uptake at day 1, 3, and 5 post stimulation with anti-CD40 plus IL-4, and 
quantification at day 0 through 5 in WT and Ampk KO B cells (n = 3). Data represent mean ± SD (B,D–G).  
P values determined by Student’s t-test (B,D–G), *P ≤ 0.05.
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Ampk is dispensable for activation-induced glucose uptake. While we did not detect differences 
in differentiation patterns of WT and Ampk KO B cells, B cell activation in response to a range of triggering 
stimuli causes increased glucose import24,27,28 and the deletion of Ampk in T effector cells reduces glucose uptake 
in vivo29. Therefore, we hypothesized that Ampk KO B cells might have defects in glucose uptake. To test this 
postulate, we utilized a fluorescent glucose analog, 2-NBDG, to measure glucose import in B cells from WT and 
Ampk KO mice that lack the Rosa26 lox-STOP-lox YFP tracer, because YFP and 2-NBDG fluorophore emission 
spectra overlap (527 nm and 540 nm, respectively). Unexpectedly, there was no difference between Ampk KO and 
WT B cells in glucose uptake during 5 days of B cell activation (Fig. 2G). Thus, Ampk activation does not regulate 
glucose import into activated B cells, suggesting an alternative glucose import mechanism.
Ampk does not affect glucose or glutamine B cell nutrients. While we did not detect differences 
in glucose uptake in Ampk KO B cells, Ampk also regulates other metabolic pathways to regulate energy stress, 
and Ampk activation at 24 hours of stimulation may impact nutrient choice or routing without affecting B cell 
differentiation or antibody responses. Therefore, we performed metabolomics profiling with 13C6-glucose and 
13C5-glutamine in resting and anti-CD40 plus IL-4 stimulated WT and Ampk KO B cells (Table S1). Principal 
component analysis (PCA) of total intracellular metabolites revealed that the major segmentation was from 
differences between stimulation time points, and not from differences between genotypes within each time 
point (Fig. 3A). We generated correlation circle plots by fitting each of the metabolites to 4 vectors based on 
the observed clustering (Fig. 3B), which indicated metabolites that are known to be changed upon activation, 
including increases in ATP with activation and decreases in the AMP/ATP ratio, consistent with prior results 
(Fig. 1C)24. With no significant differences in total metabolites between WT and Ampk KO B cells at rest or for 
any stimulated time point, we next analyzed specific 13C-isotopomer labeling. PCA of molecular IDs for isotopo-
mers (Fig. 3C, top) derived from the glucose label (left) or glutamine label (right) showed similar segmentation to 
the total metabolites, with the largest differences from stimulation time point rather than from genotype. We then 
assessed whether any biologically relevant metabolites were different between WT and Ampk KO at each time 
point. As a discovery tool, we plotted the non-corrected P-values for naïve, resting (middle row) and anti-CD40 
plus IL-4 stimulated (bottom row) B cells labeled with glucose (left) or glutamine (right) (Fig. 3C). The data failed 
to identify any biologically relevant differentially produced isotopomers (DPIs) linked to known functions of 
Ampk. These labeling patterns occurred despite >90% uptake of labeled glucose or glutamine in each respective 
experiment for all conditions examined (Fig. 3D). To further investigate whether there were any DPIs between 
WT and Ampk KO B cells irrespective of time point, we calculated P-values and could not identify metabolites 
below the corrected false discovery rate of 0.05 (Fig. 3E). We considered that some broad metabolic differences 
may not be discernible at the individual DPI level, and small changes may accumulate and reveal deficiencies or 
surpluses in whole pathways. We therefore performed Metabolite Set Variation Analysis (MSVA) utilizing curated 
KEGG metabolic pathways and again identified significant changes occurred only between naïve and stimulated 
B cells, with no separation by genotype (Fig. 4F). Together, these results show that Ampk is not modulating 
metabolism during B cell activation, despite known metabolic roles related to glucose metabolism.
Ampk regulates IgD levels but not transcripts controlling B cell fate. Additional canonical Ampk 
substrates include Hdac4 and Hdac5, proteins that deacetylate histones and thereby regulate gene expression30. 
To assess potential differences in steady-state RNA expression, and to investigate potential alternative processes 
regulated by Ampk, we performed RNA-Seq in WT and Ampk KO B cells on culture days 0 through 5 using 
anti-CD40 plus IL-4 stimulation (Table S2). At day 0, there are no PCA plotted statistical differences between 
WT and Ampk KO naïve B cells. However, as B cells differentiate from day 1 through day 5, Ampk KO B cells 
cluster separately from their WT counterparts, but follow a similar trajectory towards differentiation (Fig. 4A). 
We confirmed reduced Prkaa1 expression in Ampk KO B cells, as expected (Fig. 4B). To determine whether loss 
of Ampk conveyed a specific gene signature during 5 days of differentiation, we analyzed differentially expressed 
genes (DEGs) for days 0 through 5 of stimulation and identified 168 genes that were either consistently increased 
or decreased each day in Ampk KO compared to WT B cells (Fig. 4C). Pathway enrichment analysis of these 
168 genes did not reveal any pathways related to B cell activation or differentiation, with the exception of 5 
genes linked to apoptotic signaling in response to endoplasmic reticulum stress (Grina, Atf4, Trib3, Lrrk2, Chac1) 
(Table S2). Endoplasmic reticulum stress has an important role in plasma cell differentiation and antibody secre-
tion31. Therefore, we analyzed activation, GC B cell, and antibody-secreting cell (ASC) gene expression signa-
tures32,33 as previously reported in our data set (Fig. 2D). Similar to our earlier data, Ampk KO and WT B cells 
activate similarly and increase GC-signature transcripts equally. Expression of ASC signature genes were similar 
between WT and Ampk KO samples (Fig. 4D), although Ampk KO B cells showed increases in some ASC tran-
scripts, including Prdm1 at days 4 and 5 (Fig. 4D). This finding is consistent with a trend towards an increase in 
plasmablasts at day 5 (Fig. 2D), and a divergence in the PCA plot of days 4 and 5 WT versus Ampk KO B cells 
(Fig. 4A).
Because of the potential for increased ASCs in Ampk KO mice, despite similar amounts of secreted IgM and 
IgG1 from in vivo immunizations (Fig. 2F), we evaluated the levels of immunoglobulin transcripts in WT and 
Ampk KO B cells. We determined that heavy chain variable (Ighv) region expression levels were similar for WT 
and Ampk KO B cells, although there was an increase in some transcripts including Ighv6-3 and Ighv14-3 in 
Ampk KO B cells (Fig. 5A). From in vivo immunization data, we also detected a slight but insignificant increase 
in secreted IgM, so we analyzed transcripts for immunoglobulin constant regions to identify potential isotype 
biases. Whereas Ighm transcripts matched our observations in vivo with a minor but insignificant increase at day 
5 for Ampk KO versus WT B cells, we were surprised to discover that Ighd expression was severely repressed in 
Ampk KO B cells from day 1 stimulation onwards (corrected P-value = 9.5 × 10−30 at day 1) (Fig. 5B). IgD is nor-
mally co-expressed with IgM on the surface of all mature, naïve B cells, and is a relatively understudied antibody 
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Figure 3. Ampk does not control metabolism during B cell stimulation. (A) PCA from UHPLC-MS metabolomics 
analysis of total metabolites isolated from naïve and stimulated B cells from WT and Ampk KO mice. (B) K-means 
clustering analysis of variable loading plots, indicating the contribution of metabolites to variation across principal 
components in four groups (k = 4). Projection arrow tips indicate Pearson correlation of the listed metabolite. 
Transparency denotes cosine2 value or the strength of metabolite representation. Shown are the top 4 metabolites 
contributing to each cluster. (C) Principal component analysis and volcano plots of UHPLC-MS metabolomics 
of 13C6-glucose labeled or 13C5-glutamine labeled isotopomers (MID) in naïve and stimulated B cells from WT 
and Ampk KO mice. Plotted are non-corrected P values for KO/WT amounts of specific isotopomers (n = 3). 
(D) Isotopomer distribution of labeled glucose or labeled glutamine in naïve or stimulated WT and Ampk KO B 
cells shows uptake of labeled respective carbon source. (E) Quantification of Differentially Produced Isotopomers 
(DPIs) analyzed both by day and by genotype shows no DPIs between genotypes, only between time points for 
uncorrected or Benjamini-Hochberg corrected P values < 0.05. (F) Heatmap of significant (Benjamini-Hochberg 
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class that has potential implications in mucosal immune responses34. The expression of IgD is not impacted by 
activation-induced cytidine deaminase (AID) like most isotype switched immunoglobulins but is instead regu-
lated by Zfp31835,36. Interestingly, the most robust DEGs at day 3 are Ighd and Zfp318, each of which are greater 
than an order of magnitude more repressed than the next most differentially expressed genes (Fig. 5C). In fact, 
Zfp318 expression is repressed throughout the stimulated time course in Ampk KO B cells (Fig. 5D), coinciding 
with the drop in Ighd expression (Fig. 5B). Further supporting the specificity of Ampk loss on Zfp318 regulation 
of Ighd levels, expression of Aicda, encoding AID which regulates CSR, is the same in WT and Ampk KO B cells 
from days 0–4 and increased on day 5 of B cell activation (Fig. 5D). To confirm that the loss of Ighd transcripts 
affects IgD protein levels, we analyzed surface expression over 5 days of differentiation by flow cytometry, which 
shows that Ampk KO B cells have decreased IgD expression from days 2 through 5, particularly evident for the 
loss of IgD-high B cells (Fig. 5E). Given the limited number of DEGs, it appears that Ampk exerts highly specific 
control of IgD during B cell activation, likely through regulation of Zfp318 expression.
Pharmacological activation of Ampk. The limited scope of impact for Ampk loss on B cell physiology 
seems surprising, so we examined whether the timing of Ampk activation could regulate B cell functions. We uti-
lized two pharmacological activators of Ampk, phenformin and A-769662, to alter the timing of Ampk activation. 
Phenformin is a mitochondrial electron transport chain complex I inhibitor that activates Ampk by inhibiting 
ATP production, thereby increasing AMP/ATP and ADP/ATP ratios, and is an analogue of the diabetes drug 
metformin, whereas A-769662 is a direct and specific activator of Ampk23. We examined early activation of Ampk 
by treating B cells with each activator at the time of anti-CD40 plus IL-4 stimulation in culture and observed that 
both drugs decreased CD86 activation biomarker expression, but only phenformin reduced CD69 expression 
(Fig. 6A). Phenformin had a drastic effect on B cell differentiation by day 3 with greatly decreased CSR to IgG1 
and inhibited differentiation into GC-like B cells (Fig. 6B). By contrast, A-769662 had little effect on GC-like B cell 
differentiation and only a slight defect in CSR (Fig. 6B). These results show that electron transport chain activity 
and ATP production per se, and not accelerated Ampk activation, are critical for B cell activation, differentiation, 
and CSR, in agreement with an effect mainly targeting markedly reduced Zfp318 and Ighd expression levels in 
stimulated Ampk KO B cells (Fig. 5).
Because of recent interest in using metformin and phenformin clinically to treat B cell malignancies37, we 
further evaluated the impact of phenformin on B cell function. To determine whether the effects of phenformin 
in vitro replicate in vivo, we immunized mice with NP-(28)-CGG to induce a T cell-dependent humoral immune 
response while delivering phenformin or sucralose vehicle in the drinking water (Fig. 6C). In vivo results show 
that 14-day treatment with phenformin substantially decreased the percentage of GC B cells in the spleen and 
reduced the percentage of IgG1+ isotype switched B cells (Fig. 6D). Interestingly, however, mice on phenformin 
had similar amounts of total IgM and IgG1 in their serum (Fig. 6E). There was a minor but non-significant 
defect in the generation of NP8-specific high affinity IgG1 antibody in phenformin treated mice, but no effect on 
broader NP20 IgG1 antibodies (Fig. 6F). Overall, these findings suggest that phenformin reduces GC formation, 
but still allows for generation of antigen-specific antibody production.
Discussion
Our recent results showing that loss of Lkb1 kinase signaling triggers the B cell GC reaction4,5 prompted studies 
of Ampk as a main Lkb1 target kinase during B cell activation. We found Ampk activation 24 hours after stimu-
lation of naïve B cells with anti-CD40 antibody plus IL-4 (Fig. 1A). A key role for activated Ampk in mammalian 
cells is to block anabolic processes that consume energy by target protein phosphorylation in response to energy 
stress. To our surprise, B cell activation with rapid biomass accumulation and cell proliferation coincides with 
sustained Ampk activation in the absence of energy stress (Fig. 1A,B). We anticipated the opposite result, that 
Ampk activity would prevent biomass accumulation. While unexpected given the canonical targets and activities 
of Ampk, including inhibition of major anabolic targets Acc1, Tsc2, and Raptor, these findings also make sense 
in the biological context of B cell activation. For example, the Ampk target Raptor is essential for Bcl6 expression 
and recruitment of activated B cells into GCs38, and inhibition of Raptor by Ampk at this time would prevent 
GC formation. Similarly, Ampk-driven inhibition of protein and lipid synthesis through Acc1 and Tsc2 would 
antagonize the need for biomass accumulation while B cells prepare for rapid division in the GC24,39,40. While acti-
vation of Ampk during B cell activation was unexpected due to the role of Ampk in biomass accumulation, there 
are precedents for Ampk activation in other immune contexts. For example, in T cells, Ampk is transiently and 
immediately activated after CD3 or calcium stimulation13, and Ampk phosphorylation declines in proliferating 
T effector cells14. This contrasts with B cells, where Ampk activation after 24 hours of stimulation persists dur-
ing proliferation (Fig. 1A). In T cells, Ampk activation by nutrient limitation, metformin treatment, or AICAR, 
results in decreased IFN gene transcription and reduced T cell effector function29. Here, activation of Ampk by 
phenformin prevents GC differentiation and CSR, but still allows for generation of high-specificity antibodies 
(Fig. 6A–E).
FDR adjusted P value < 0.05) metabolite set variation analysis (MSVA) pathway activity scores across WT and 
Ampk KO naïve and stimulated B cells for curated KEGG metabolic pathways. Data represent the mean ± SD (D) 
of relative metabolite amounts from n = 3 independent experiments. Data from separate glucose and glutamine 
labeling experiments were pooled, and relative amounts analyzed for (A,B). P values determined by Student’s t test 
(C), 2-way ANOVA with Bonferroni correction for multiple comparisons (D), or empirical Bayes with Benjamini-
Hochberg correction for multiple comparisons (F).
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To study Ampk during B cell activation in vivo, we made a B cell specific KO of the catalytic Ampk alpha sub-
unit, Prkaa1 that achieved >80% deletion efficiency, but did not detect a phenotype similar to B cell specific Lkb1 
KO mice4. In fact, Lkb1 loss increases CSR and decreases plasmablast differentiation, whereas Ampk loss instead 
decreases CSR and slightly increases plasmablast differentiation (Figs 2D, 4D). These results suggest that Lkb1 
acts through substrates other than Ampk to regulate B cell activation and GC formation, or that other related 
Lkb1 targets may compensate for the loss of Ampk. For example, Lkb1 phosphorylates 13 other Ampk family 
member proteins including Mark, Brsk, and Nuak proteins7. Sik2 and Mark2 are Lkb1 targets that phosphorylate 
Crtc241, a transcriptional co-activator of CREB required for GC exit42, and their redundant activity might com-
pensate for the loss of Ampk to rescue plasma cell differentiation.
We were further surprised to find no evidence for Ampk in regulating metabolism in B cells. Nutrient uptake 
and routing was identical in WT and Ampk KO B cells (Figs 2G, 3). One possibility is that Ampk is dispensable for 
Figure 4. B cell activation and differentiation expression signatures are maintained despite loss of Ampk. (A) 
PCA from bulk RNA sequencing analysis of total RNA isolated from day 0 through day 5 stimulated B cells 
from WT and Ampk KO mice. PC1 and PC2 are shown. (B) Kinetic time course expression plot of Prkaa1 
during stimulation. (C) Heat map of KO signature gene expression across averaged samples. KO signature 
was generated as the intersection of all KO/WT DEGs at each time point from day 1 to day 5 of stimulation 
(adjusted P value < 0.05, abs(log2FC) >0.5 at each time point comparison). (D) Heat maps for B cell activation, 
germinal center, and ASC gene signatures from32,33,55. Genes shown were selected as the top 55 differentially 
expressed from the Shi 2015 signatures between WT day 0 and day 2 (activation), WT day 0 and day 3 (GC), 
and WT day 0 and day 5 (ASC), with Prdm1 included post hoc. Pathway scores represent total GSVA enrichment 
of the respective Shi 2015 signatures for each comparison (adjusted P value < 0.05). Heat map values represent 
row z-score (n = 3 each WT and KO for each time point). Adjusted P values determined by Wald test (B). 
****P ≤ 0.0001.
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homeostatic nutrient handling but required for metabolic adaptations under stressful conditions not examined 
here. Supporting this idea, studies in T cells show that Ampk can regulate glutamine metabolism during glucose 
deprivation29 and total body knockout of Ampk makes B and T cells unable to survive ATP synthase inhibition 
with oligomycin21. Recent studies show that GCs in mice are hypoxic microenvironments43 and Ampk links to 
inflammation in hypoxia44. Resting and activated Ampk KO B cells express genes and gene profile signatures sim-
ilar to WT B cells, except for two repressed transcripts, Zfp318 and Ighd. This specificity is remarkable and rep-
licates the specificity of Zfp318 KO B cells, in which there were only two differentially expressed genes, Ighd and 
Figure 5. Ampk specifically regulates expression of IgD via downregulation of Zfp318 during activation. (A) 
Heat maps for immunoglobulin heavy-chain variable region expression (Ighv) across naïve and day 4/day 5 
stimulated B cells. Genes were selected based on significant differential expression between WT naïve and day 5 
stimulation (adjusted P value < 0.05). Values represent row z-score. (B) Kinetic time course expression plots for 
immunoglobulin heavy-chain constant region (Igh) expression across genotype and stimulation. (C) Volcano 
plot of differentially expressed genes between Ampk KO and WT at day 3 of stimulation. Adjusted P value 
cutoff represents values < 0.05 calculated using the Wald test following DESeq2 normalization. (D) Kinetic time 
course expression plot of Zfp318 and Aicda across genotype and stimulation. (E) Representative flow cytometry 
plot of IgD at day 0 through day 5 of stimulation in WT and Ampk KO B cells and quantification by MFI (top) 
and % IgD (bottom) (n = 3 each WT and Ampk KO). P values were determined by Student’s t-test (E), adjusted 
P values were determined by Wald test (B,D) *P ≤ 0.05, **P ≤ 0.01, **P ≤ 0.001, ***P ≤ 0.0001.
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Figure 6. Early pharmacological activation of Ampk modifies B cell function both in vitro and in vivo. (A,B) 
Representative flow cytometry plots and quantification of activation markers (CD86, CD69) at 24 hours (A), and 
germinal center differentiation (GC B Cells, %B220+ Fas+ GL7+) and class switch recombination (CSR, %B220+ 
IgG1+) at day 3 (B) of cells during in vitro activation with anti-CD40 plus IL-4 and phenformin (100 µM) or 
A-769662 (50 µM) (n = 3). (C) Strategy for in vivo assessment of B cells responses with Ampk activation. Prior to 
immunization, mice were given phenformin or vehicle (sucralose) in their water. Water was changed 2×/week, and 
samples collected 14 days post immunization with NP-(28)-CGG. (D) Flow cytometry of total splenocytes after 
immunization. Representative plots and quantification of GC differentiation (GC B Cells, B220+ Fas+ GL7+) and 
CSR (B220+ IgG1+) 14 days post-immunization with NP-(28)-CGG (n = 4). (E) Anti-NP8 and anti-NP32 IgG1 
serum response and NP8/NP32 IgG1 ratio by ELISA 14 days after immunization with NP-(28)-CGG (n = 4). Data 
represent mean ± SD. P values determined by 2-way ANOVA with Bonferroni correction for multiple comparisons 
(A,B), or Student’s t-test (D,E), *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.
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Sva, an antigen related to the Vav-Cre recombinase deletion construct35. Loss of Ighd transcripts parallels a loss of 
surface IgD protein expression in the Ampk KO B cells after stimulation. A possible but less likely contributor to 
a difference in later time point IgD expression between WT and Ampk KO B cells could be differential increase in 
cell death in the in vitro culture system between days 4 and 5 of stimulation. The role(s) of IgD in B cells remains 
elusive, as IgD is present at very low levels in human and rodent serum45, but has recently been suggested to 
modulate Th2 responses to soluble antigens through interactions with basophils46. Because of co-expression of 
IgM and IgD in immature B cells, IgD may sequester signaling molecules from IgM to inhibit BCR signaling47, 
and IgD may play a similar role in mature B cells. Regardless of the role of IgD, the specific regulation of Zfp318 
and Ighd by Ampk provides new insight into immunoglobulin gene regulation as a non-canonical role for Ampk.
Materials and Methods
Mice. C57BL/6J, Prkaa1fl/fl, CD19-Cre, and Rosa26 lox-STOP-lox EYFP mice (JAX: 000664, 014141, 006785, 
and 006148) were housed in a specific pathogen-free animal facility at UCLA. All studies were on mixed-sex mice 
between 6 to 16 weeks of age with approval from the UCLA Institutional Animal Research Committee (#1998-
113-63C). All experiments were performed according to the National Institutes of Health and ARRIVE guide-
lines on the use of laboratory animals. Figures 1, 6 used WT C57BL/6J mice, and Figs 2–5 used B cell specific 
Ampk KO or Ampk WT littermate mice. Genotypes for WT (Prkaa1+/+) and Ampk KO (Prkaa1−/−) mice were 
as follows: Prkaa1wt/wt or Prkaa1fl/fl, respectively, with CD19-Cre+/−, and Rosa26-YFP+/+ or +/− for experiments 
requiring YFP (Fig. 3B–D,F) or Rosa26-YFP−/− for experiments without YFP tracer (Figs 3E,F, 4–6).
Stimulation of isolated mouse B cells. Red blood cell-lysed mouse spleen cells were enriched for B cells 
using CD43 negative magnetic selection (Miltenyi). Cells were grown in RPMI1640 supplemented with 10% 
FBS and 50 µM β-mercaptoethanol. B cells were stimulated with 1 µg/ml anti-CD40 mAb (BD Pharmingen) and 
25 ng/ml IL-4 (R&D Systems). At day 3, anti-CD40 was washed out and cells replated in medium containing only 
IL-4 until day 5. For early Ampk activation, phenformin (Sigma) was resuspended in 1x PBS, pH 7.4, and used at 
100 µM, and A-769662 (Abbott) was resuspended in DMSO and used at 50 µM at the time of stimulation.
Immunoblotting. Cells were lysed in Lysis Buffer containing 50 mM Tris HCl pH 7.4, 100 mM NaCl, 1 mM 
EDTA and 1% Triton X-100 supplemented with Protease Inhibitor and Phosphatase Inhibitor Cocktails 2 and 
3 (Sigma). Extracts were quantified and denatured by boiling with DTT and 10–30 µg protein separated by 
SDS-PAGE and transferred to nitrocellulose before blocking in 5% milk in TBST. Membranes were incubated 
overnight in the indicated antibodies in 5% BSA in TBST. Membranes were then incubated in fluorescent second-
ary antibody and imaged using the Odyssey Fc imaging system (LI-COR). Complete antibody information can 
be found in the Supplemental Methods.
Flow cytometry. Single cell suspensions were incubated with Fc Block (BD Pharmingen) at 1:500 for 15 min, 
then washed and stained for 20 min in 50 µl FACS buffer (2% FBS in PBS) on ice in the dark. Data were obtained on a 
BD LSRII or BD Fortessa (BD Biosciences) and analyzed with FlowJo software (Treestar). Antibodies were used at a 
1:200 dilution. Complete antibody information can be found in the Supplemental Methods. Assessments of glucose 
import used a 2-NBDG Glucose Uptake Assay Kit (Biovision) according to the manufacturer’s instructions.
Extracellular metabolite analysis. Glutamine levels in full media and after 24 hours of stimulation were 
measured by plating 106 cells/ml in 2 ml, centrifuging to remove cells and debris, and analyzing using a BioProfile 
Basic Analyzer (NOVA Biomedical).
Live cell interferometry. Live cell interferometry (LCI) was used to measure biomass accumulation rate25. Cells 
were plated at 7.5 × 105 cells/ml on Poly-L-Lysine (Sigma) coated µ-Slide 2-Well Ph+ glass bottom slides (Ibidi) and 
imaged every 15 min for 72 h in a custom-built chamber as previously described48. LCI was performed on a Zeiss 
Axio Observer A1 with stage-top incubation system (Zeiss) using using a 20 × 0.4 NA objective. LCI data were cap-
tured with a SID4Bio (Phasics) QWLSI camera49. MATLAB (Mathworks) was used to analyze LCI data. Quantitative 
phase microscopy data was processed using SID4Processing (Phasics) to generate phase-shift images compatible with 
MATLAB. A custom MATLAB script was used to track the mass of individual cells as previously described50.
Immunization and ELISA. Mice were immunized with 50 µg NP-(28)-CGG (Biosearch Technologies) 
in ImJect Alum (Thermo Scientific) via intra-peritoneal injection. Blood was collected at 14 days and assayed 
by ELISA. Serum Ig concentrations were determined using anti-mouse Ig as a capture antibody and developed 
with isotype-specific goat anti-mouse antibodies conjugated to HRP (Southern Biotech). Antigen-specific ELISA 
was performed by coating a plate with NP-(8)- or NP-(20)-BSA and developed with an isotype specific goat 
anti-mouse antibody conjugated to HRP. For immunizations with phenformin, mice were given water containing 
either vehicle (5 mg/ml sucralose, Sigma) or phenformin (1.8 mg/ml, Sigma) with vehicle in amber bottles one 
day before immunization, and water was changed twice per week.
Metabolomics. B cells were grown for 24 hours in media with glucose or glutamine free RPMI (Gibco) sup-
plemented with 2 g/L [U-13C] glucose or 3 mM [U-13C] glutamine, respectively (Cambridge Isotope Laboratories) 
and non-dialyzed FBS. Metabolites were extracted with cold 80% methanol and measured using Ultra High 
Performance Liquid Chromatography Mass Spectrometry (UHPLC-MS), as previously described24,51,52. To 
extract intracellular metabolites, cells were pelleted by centrifugation (1000 RPM, 4 °C) and rinsed with cold 
150 mM ammonium acetate (pH 7.3), pelleted again, followed by addition of 1 ml cold 80% MeOH in water. To 
the cell suspensions, 10 nmol D/L-norvaline were added and rigorously mixed followed by centrifugation 
(1.3 × 104 rpm, 4 °C). The supernatant was transferred into a glass vial and pellet was further extracted with 200 µl 
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cold 80% MeOH in water. After centrifugation, supernatant was combined, metabolites dried down under vac-
uum, and resuspended in 70% acetonitrile. For the mass spectrometry-based analysis of the sample, 5 µl were 
injected onto a Luna NH2 (150 mm × 2 mm, Phenomenex) column. The samples were analyzed with an UltiMate 
3000RSLC (Thermo Scientific) coupled to a Q Exactive mass spectrometer (Thermo Scientific). The Q Exactive 
was run with polarity switching (+3.50 kV/−3.50 kV) in full scan mode with an m/z range of 65–975. Separation 
was achieved using A) 5 mM NH4AcO (pH 9.9) and B) ACN. The gradient started at 15% A) going to 90% A) 
over 18 min, followed by an isocratic step for 9 min and reversal to the initial 15% A) for 7 min. Metabolites and 
isotopomers thereof were quantified with TraceFinder 3.3 using accurate mass measurements (≤3 ppm) and 
retention times. For isotopologue distribution measurements, data was corrected for naturally occurring 13C as 
described in53. Fractional contributions were calculated using the formula = ∑
∑
⁎FC i mn m
n
i
n
i
0
0
 as described54, where mi 
denotes the intensity of the isotopologue, and n marks the number of carbons in a given metabolite. Data were 
normalized to cell counts. Metabolite relative amounts, isotopomer distribution values, MSVA scores, and DPI 
lists are included in a supplemental excel file (Table S1).
RNA extraction. At least 107 WT and Ampk KO B cells were grown in biological triplicates and RNA purified 
immediately after isolation, or 24 hours after anti-CD40 plus IL-4 stimulation using the RNeasy Mini Kit (Qiagen) 
and RNase-free DNase (Qiagen) following the manufacturer’s protocols. All samples showed an A260/280 ratio 
>1.99. Prior to library preparation, quality control of the RNA was performed using the Advanced Analytical 
Technologies Fragment Analyzer (Advanced Analytical, Inc.) and analyzed using PROSize 2.0.0.51 software. 
RNA Quality Numbers (RQNs) were computed per sample between 8.7 and 10, indicating intact total RNA per 
sample prior to library preparation.
RNA-seq library preparation. Strand-specific ribosomal RNA (rRNA) depleted RNA-Seq libraries were 
prepared from 1 µg of total RNA using the KAPA Stranded RNA-Seq Kit with Ribo-Erase (Kapa Biosystems, 
Roche). Briefly, rRNA was depleted from total RNA samples, the remaining RNA was heat fragmented, and 
strand-specific cDNA was synthesized using a first strand random priming and second strand dUTP incor-
poration approach. Fragments were then A-tailed, adapters were ligated, and libraries were amplified using 
high-fidelity PCR. All libraries were prepared in technical duplicates per sample and resulting raw sequencing 
reads merged for downstream alignment and analysis. Libraries were paired-end sequenced at 2 × 150 bp on an 
Illumina NovaSeq 6000.
Lists of transcript/gene-level expression values, KO signature ORA results, and differentiation signature GSVA 
results are included in a supplemental excel file (Table S2).
Statistical analyses. All metabolomics and transcriptomics statistical analyses are described in the above 
methods. Values represent mean ± S.D. or S.E.M. Data were analyzed with Prism 6 (GraphPad) (Figs 1–3, 6), 
MATLAB (Mathworks) (Fig. 1E–G) or R (Figs 3–5). Parametric data were analyzed using unpaired two-tailed 
Student’s t-tests, or 2-way ANOVA with Bonferroni correction for multiple comparisons. Transcriptomic volcano 
and kinetic time course expression plots were analyzed using DESeq2 Wald tests with Benjamini-Hochberg FDR 
correction for multiple comparisons. For all data sets, P ≤ 0.05 was considered significant. *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001, ****P ≤ 0.0001.
Data Availability
All raw RNA-Seq reads, transcript abundance values, and processed gene count matrices were submitted to the 
NCBI Gene Expression Omnibus (GEO) under accession GSE121025. All metabolomics and downstream tran-
scriptomics datasets have been provided as supplemental material in this study (Tables S1 and S2).
Code Availability
All custom code used for metabolomic/transcriptomic analyses are available on Atlassian BitBucket at http://bitbucket.
org/ahsanfasih/AmpkBcell/src/master and detailed descriptions of data analysis can be found in the Supplementary 
Methods.
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